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ABSTRACT 
Telomeres are repetitive DNA sequences found at the ends of eukaryotic 
chromosomes that help maintain genome stability. Telomeres shorten every 
time a cell divides, eventually inducing replicative senescence. To gain 
replicative immortality cancer cells establish mechanisms to maintain telomere 
length over many cell divisions. Around 10% of cancers do this using a 
recombination-based pathway called the Alternative Lengthening of Telomeres 
(ALT). ALT resembles a specific type of homology-directed repair called break-
induced replication (BIR). Through this body of work, we aimed to better 
understand both the genetics underlying ALT positive cancers and the 
mechanistic basis of ALT. ALT positive cancers frequently carry loss of function 
mutations in the genes for ATRX/DAXX, which function to regulate 
heterochromatin. Recently, we identified a novel chromosomal fusion event in 
ALT positive osteosarcoma causing defects in DAXX function. Additionally, we 
identified several osteosarcoma tumors with wild-type ATRX/DAXX that had 
abnormalities in SLX4IP or SMARCAL1, proteins recently shown to regulate the 
ALT pathway. These data suggest that a more thorough understanding of the 
	
	 x 
ALT mechanism may reveal additional factors that are defective in ALT positive 
tumors. Building on this, we aimed to further define the mechanism of ALT by 
investigating the DNA translocase RAD54 in the ALT pathway. During BIR, a 
broken DNA strand invades a homologous template, forming a structure called a 
displacement loop (D-loop) where a strand of template DNA is displaced to 
allow base pairing between the broken DNA strand and the homologous 
template. The D-loop recruits DNA polymerases, leading to extension and repair 
of the broken DNA strand. RAD54 is known to regulate both the formation and 
resolution of D-loops. In this work, we found that RAD54 promotes elongation at 
ALT telomeres by mediating branch migration and dissolution of the D-loop. D-
loops formed at ALT telomeres must be resolved before mitosis to prevent the 
formation of ultra-fine anaphase bridges. These data demonstrate that by 
mediating D-loop migration RAD54 plays an important role in both promoting 
telomere elongation and maintaining genome stability in ALT cells. Together this 
body of work represents advances in defining both the genetic and mechanistic 






Portions of Chapter 1 are reproduced from a book chapter that I wrote. Chapter 
2 is reproduced from two published papers, one of which I am first author and 
one of which I contributed as a co-author, with Chapter 2 highlighting my 
contributions as a co-author. Chapter 3 is reproduced from a manuscript of 
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CHAPTER ONE: INTRODUCTION 
Parts of this chapter are reprinted by permission from Springer Nature: adapted 
from Mason-Osann E, et al. Methods in Molecular Biology, 1999(31-57) ©2019  
Section 1: Telomere structure and function 
 Telomeres are repetitive DNA elements found at the ends of eukaryotic 
chromosomes that function to protect genome integrity. In mammalian cells, 
telomeres are composed of sequential TTAGGG hexanucleotide repeats, which 
are typically 10-15 kilobases in length.(1) Although predominantly double-
stranded, telomeres contain a 150-200 nucleotide single stranded 3’ overhang 
that loops back to invade the more centromere proximal telomeric DNA 
sequence, forming a T-loop structure.(2) (Fig 1.1A) The T-loop structure is 
supported by a protein complex called shelterin, which binds and coats telomeric 
DNA.(3, 4) The shelterin complex is made up of six proteins, TRF1, TRF2, POT1, 
TPP1, RAP1, and TIN2, which, in addition to stabilizing the T-loop, functions to 
protect mammalian telomeres from degradation and to prevent telomeres from 
eliciting a DNA damage response. (Fig 1.1B)(3) TRF1, TRF2, and POT1 bind 
directly to the telomeric DNA with sequence specificity. While TRF1 and TRF2 
bind the double stranded regions of telomeric DNA, POT1 binds single stranded 
telomeric DNA. TIN2, TPP1, and RAP1 act as stabilizing proteins, and function to 
recruit other proteins crucial for telomere homeostasis.(3, 5)  
The telomere functions to protect eukaryotic cells against two important 




chromosomes. First, eukaryotic cells cannot distinguish between the ends of 
linear chromosomes and DNA double strand breaks (DSBs).  In the absence of 
functional telomeres, chromosome ends are treated as DNA DSBs and repaired 
through non-homologous end joining (NHEJ), causing chromosomal end-to-end 
fusions.(6–8) Fused chromosomes break as the cell proceeds through mitosis, 
leading to either cell death or large-scale chromosomal abnormalities and 
genome instability. Together the T-loop and shelterin repress DNA repair 
processes at the telomere, helping to make the telomere biologically distinct from 
a DNA DSB. The strand invasion event that leads to T-loop formation physically 
obscures the double stranded end of the chromosome, thereby preventing 
activation of NHEJ.(4, 5) Additionally, both the double-stranded chromosome end 
and the single-strand DNA overhang found at telomeres are capable of eliciting a 
DNA damage response through ATM and ATR, two kinases that are central to 
coordinating cellular response to DNA damage.(9) Shelterin coats both the 
double-stranded and single-stranded telomeric DNA to prevent the activation of 
ATM and ATR, thereby repressing DNA damage response at the telomere. (3, 9)  
The second source of genome instability inherent to the eukaryotic 
genome is caused by the nature of DNA replication. Linear chromosomes cannot 
be replicated entirely at their terminal ends, leading to a loss of chromosomal 
DNA from the end of every chromosome each time a cell proceeds through the 
cell cycle.(10–12) The telomere does not prevent this loss of DNA, but acts as a 






Figure 1.1 – Telomere structure and the shelterin complex.  
A) Depiction of linear telomeric DNA showing the G-rich ssDNA overhang. (Top) The G-rich 
ssDNA overhang is capable of invading the more centromere proximal telomeric DNA, to 
hide the chromosome end and form the T-loop structure.  (Bottom) 
B) Shelterin is a 6 protein complex made up of TRF1 and TRF2, which bind double stranded 
telomeric DNA, POT1, which binds single stranded DNA, TPP1, TIN2 and RAP1.  POT1 
represses ATR activation and TRF2 represses ATM, together preventing activation of 





























regulatory information, cells lose telomeric repeats each time the cell divides. 
This manifests as telomere shortening over successive cell divisions.(13, 14) 
Eventually, shortened telomeres are no longer able to repress DNA damage 
response, likely due to insufficient shelterin binding.(15, 16) In normal somatic 
cells, shortened telomeres activate DNA damage checkpoints, leading to 
permanent exit from the cell cycle into a metabolically active but non-dividing 
state called cellular senescence. Telomere stability is important for maintaining 
both the integrity of eukaryotic genomes, and the proliferative capacity of 
eukaryotic cells. 
 
Section 2: Replication stress and the cellular response 
DNA replication 
Genome stability in eukaryotic cells relies on accurate and efficient 
replication of the DNA during the synthesis phase (S-phase) of the cell cycle. The 
initiation of DNA replication is a highly coordinated and tightly regulated process 
that consists of two main phases, the licensing of replication origins and the 
subsequent firing of those origins. During licensing, a multi-protein complex 
referred to as the pre-replicative complex (pre-RC) is assembled at origins of 
replication. The mammalian pre-RC is made up of the DNA binding origin 
recognition complex (ORC), Cdc6, and two inactive helicase complexes made of 
MCM2-7, which are sequentially recruited to origins.(17–22) Cdt1 is required for 




complex. As cells enter into S-phase, components of the pre-RC are dissociated 
and/or degraded, preventing origins from licensing more than once per cell cycle 
and ultimately preventing rereplication.(23) In human cells, this regulation is 
thought to be mediated primarily through inactivation/degradation of the pre-RC 
component Cdt1.(24–27)  
Origin firing and the initiation of DNA synthesis requires the assembly of 
additional regulatory proteins and the DNA replication machinery specifically at 
licensed origins. This process is regulated by two key kinases, S-phase CDK and 
Cdc7-Dbf4 (DDK).(28, 29) These kinases phosphorylate MCM2-7 to promote 
recruitment of GINS and Cdc45, thereby forming the highly active CMG complex 
(Cdc45 – MCM2-7 – GINS) that travels with the replication fork and functions as 
the replicative helicase.(30) Full assembly of the replisome requires the 
recruitment of other factors, including the single stranded DNA (ssDNA) binding 
protein replication protein A (RPA), DNA polymerase α-primase (Pol α), leading 
strand polymerase (Pol ε), and lagging strand polymerase (Pol δ).(31, 32) Origins 
are fired and the complete replisome is assembled following the onset of S-
phase. A subset of licensed origins will become active and fire during S-phase, 
(17, 33)  while the remainder of origins will remain dormant, only firing if the 
integrity of a neighboring replication fork is compromised.(34, 35)  
Upon origin firing, the double stranded DNA (dsDNA) at the replication 
origin is melted to create a replication bubble and two bidirectional replication 




promotes the formation of ssDNA which, if left unprotected, threatens genome 
stability.(36) Thus, the exposed ssDNA formed at the replication fork is bound by 
RPA. The formation of RPA-coated ssDNA plays an important role not only in 
binding and protecting the ssDNA, but also in stabilizing the replication fork 
itself.(37–39) The replication fork and active replisome, containing the CMG 
complex, the DNA binding clamp proliferating cell nuclear antigen (PCNA), and 
DNA polymerases, travels bidirectionally away from the origin of replication. The 
CMG complex unwinds dsDNA ahead of Pol ε and Pol δ to facilitate the 
synthesis of new copies of each individual DNA strand.(40) Pol ε synthesizes the 
leading strand of DNA continuously in the 5’-3’ direction, while Pol δ synthesizes 
discontinuous fragments of DNA called Okazaki fragments to generate the 
lagging strand. Each Okazaki fragment is initiated at an RNA primer generated 
by Pol α/Primase on the lagging strand.(40) The RNA primers generated by Pol 
α/Primase are later removed and filled in with DNA nucleotides, and the Okazaki 
fragments are ligated together to form a continuous DNA strand.  
Replication stress 
There are a number of inherent challenges to replication that arise as 
byproducts of normal cellular metabolism, causing the slowing or stalling of 
replication forks, or replication stress. While replication stress can be resolved 
through a number of different mechanisms, persistent replication stress can lead 
to the formation of DNA damage, such as DNA DSBs. Innately, certain parts of 




levels of DNA damage in the presence of low levels of replication stress.(41–44) 
These sites, called common fragile sites (CFS), are stable in unperturbed cells 
but under low levels of replication stress show evidence of chromosomal breaks 
and are frequently sites of recombination. (41, 45–47) In addition to CFS loci, 
there are a number of other naturally occurring impediments to the replication 
machinery, including bulky DNA adducts, G-quadruplexes (G4s), DNA hairpins, 
DNA mismatches, DNA nicks and/or ssDNA gaps, transcription bubbles, and 
nucleotide depletion.(48–52) These sources of replication stress act as 
roadblocks, causing slowing or stalling of the replication machinery. (48) If not 
alleviated, replication stress can cause genome instability or even cell death. To 
mitigate genome instability and complete DNA replication, cells employ a variety 
of mechanisms to manage and resolve replication stress.  
Replication stress response  
When the replication fork slows or stalls, the replicative helicase can 
dissociate from the replicative polymerases, causing DNA to be unwound well 
ahead of DNA synthesis.(53) This uncoupling can lead to the accumulation of 
long stretches of ssDNA that become bound and coated by RPA. Given the 
affinity of RPA for ssDNA, replication stress leading to the accumulation of 
ssDNA can risk depleting cellular stores of RPA, provoking a phenomenon called 
RPA exhaustion.(54) RPA exhaustion exposes unprotected ssDNA, which is 
quickly converted into DNA DSBs leading to genomic instability and, ultimately, 






Figure 1.2 – Replication stress and rescue of stalled replication forks. 
Stalled replication forks (stalled replisome indicated by red octagon) can be processed in several 
ways.  The replication fork can be restarted (restarted replisome indicated by green octagon) by 
removing the source of replication stress, such as cleaving an R-loop using RNaseH1, or 
unwinding a G4 using BLM/WRN/RTEL1.  Replication forks can be reversed with the help of 
reannealing helicase SMARCAL1, thus protecting the replication fork and aiding in fork restart.  
However, if the fork stalls irreversibly, the replisome dissociates and the replication fork collapses. 
A collapsed fork can then be processed into a DNA double strand break.  The broken fork can 
engage BIR, utilizing PCNA, Polη, and Polδ to synthesize new DNA off of a homologous 
template. This repair process results in completion of replication and also the elongation of 
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Prior to the cleavage of a stalled or collapsed replication fork into a DNA 
break, replication stress alone can activate DNA damage repair pathways. Even 
in the absence of RPA exhaustion, persistent RPA-coated ssDNA at stalled 
replication forks regulates a replication stress response by recruiting and 
activating the DNA damage checkpoint kinase, ataxia-telangiectasia mutated and 
Rad3 related (ATR) and the ATR-interacting protein (ATRIP).(39, 53, 55–60) 
ATR helps to mediate both global and local responses to repair DNA damage 
and alleviate replication stress.(48) Globally, ATR halts the cell cycle and inhibits 
origin firing by phosphorylating and activating the checkpoint protein CHK1.(54) 
Thus, ATR activation allows the cell time to resolve replication stress, restart 
stalled forks, and avoid replication catastrophe or, if the DNA damage is 
irreparable, induce apoptosis. Locally, ATR promotes the protection and restart 
of stalled replication forks, helping the cell to faithfully complete DNA 
replication.(56, 61)  Cells with persistent replication stress, such as cells that 
utilize the Alternative Lengthening of Telomere (ALT) pathway, show a 
persistence of RPA foci, and a therefore a dependence on ATR signaling.(62–64)   
Obstacles to the replication machinery can lead to both reversible and 
irreversible stalling of the replication fork. Reversibly stalled replication forks can 
be restarted by removing, resolving, or bypassing the source of replication stress, 
allowing the replication fork to proceed. (Figure 1.2) The machinery required to 
facilitate replication restart depends on the source of the replication stress and 




remove the lesion.(48) If the source of the replication stress cannot be removed, 
replication can continue across the lesion by switching out the canonical 
replicative polymerase for one of the translesion synthesis polymerases that can 
accommodate a particular lesion, promoting a DNA damage tolerance pathway. 
In addition, reversibly stalled forks can bypass certain DNA lesions by repriming 
DNA synthesis on the 5’ side of the lesion, allowing the replication fork to restart 
and continue past the lesion, leaving a section of ssDNA that is later filled in.(65) 
Finally, a reversibly stalled replication fork can be physically reversed to form a 
‘chicken foot’ structure. (Figure 1.2) The chicken foot structure has been 
suggested to protect the stalled replication fork from nucleolytic degradation by 
minimizing the exposed ssDNA at the replication fork and facilitating replication 
fork restart.(66) After stalled forks are reversed and the lesion is removed, 
resolved, or bypassed, these forks can be restarted. However, if the damage has 
compromised the ability of the fork to restart, the chicken foot can be processed 
into a DNA DSB and repaired by recombination. (Figure 1.2)(66) 
Slowing or stalling of replication forks can lead to incomplete DNA 
replication during S-phase.  Cells that enter mitosis with under-replicated DNA 
are susceptible to the formation of anaphase bridges during chromosomal 
segregation. (67–70) If left unresolved anaphase bridges can lead to 
chromosomal breakage and genomic instability in the following cell cycle.(67, 
70–72)  Given the propensity of the telomeres to undergo replication stress, and 




enzymes, such as BLM, WRN and SLX4, are recruited to telomeres to prevent 
the formation of ultra-fine anaphase bridges at the telomere.(70, 73) Induction of 
replication stress or telomere fragility increase the formation of ultra-fine 
anaphase bridges and the recruitment of BLM to telomeres.(70, 73) 
When barriers to replication lead to an irreversibly stalled replication fork, 
the replisome dissociates from the DNA, collapsing the replication fork and 
leaving the DNA vulnerable to DNA damage. If these collapsed forks are not 
repaired, these regions of DNA could persist unreplicated. Thus, the cell has 
evolved several mechanisms to rescue collapsed forks and ensure faithful 
duplication of the genome. One mechanism for the rescue of collapsed forks is 
through firing of adjacent dormant origins.(34, 35, 74–76) Dormant origins are 
already licensed and poised to initiate replication, but have not yet been fired. 
Firing of these dormant origins creates a new bidirectional replication fork which 
can converge on the adjacent stalled replication fork, restoring replication 
through that region.(34, 35) While it was previously thought that there were no 
origins of replication in telomeres, it has recently been shown that DNA 
replication can initiate within telomeric repeats,(77) indicating that dormant origin 
firing may be a mechanism to rescue collapsed replication forks in the telomeres. 
However, to date, dormant origins fired in response to telomere replication stress 
have only been observed in the subtelomeric region, the region of the 
chromosome immediately proximal to the telomere.(77) If collapsed replication 




into a single-ended DNA DSBs.(78, 79) (Figure 1.2) Single-ended DSBs are 
common substrates for break-induced replication (BIR), a specific form of 
homology-directed repair.(78, 80, 81) By breaking, collapsed replication forks can 
engage homology-directed repair in response to unresolved replication 
stress,(79) providing cells with a backup mechanism to complete DNA replication 
in the presence of irreversibly stalled replication forks. (Figure 1.2) 
Repair of collapsed replication forks by homologous recombination 
To maintain genome stability, irreversibly stalled or collapsed replication 
forks can be processed into single ended DNA DSBs,(82, 83) which then engage 
homology directed repair, such as break induced replication. The exact 
mechanism by which DNA double strand breaks are formed at irreversibly stalled 
replication forks has not been fully elucidated. However, the prevalence of 
ssDNA at stalled replication forks has suggested that both passive breakage 
and/or nucleolytic cleavage can contribute to the formation of these single ended 
double strand breaks.(48, 78, 84)   
There are two major pathways that cells utilize for repair of DNA DSBs, 
NHEJ or homology directed repair pathways, such as homologous recombination 
(HR).(80, 85) During NHEJ, blunt ends of DNA are ligated, often introducing 
small DNA insertions or deletions at the site of the DSB, thus making it an error-





Figure 1.3 – Repair by homologous recombination 
During pre-synapsis DNA double strand breaks undergo long-range resection through the 
combined action of MRN/CtIP and BLM/DNA2/EXO1. Following resection, 3’ single stranded 
overhang promotes strand invasion and synapsis. Strand invasion can be either RAD51-
dependent or RAD51-independent. Break-induced replication is likely to utilize RAD52 to promote 
synapsis of the broken DNA strand with template DNA. Strand invasion results in the synapsis of 
a plectonemic D-loop. Two-ended DNA double strand breaks can then undergo second end 
capture to create a double Holliday junction (HJ) structure, which can be resolved by either 
dissolution or resolution. D-loops formed by single-ended DNA double stranded breaks undergo 
break-induced replication. D-loops can be resolved in two ways during break-induced replication. 
Branch migration of D-loops promotes DNA synthesis and dissolution of the D-loop. Alternatively, 
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homologous DNA molecule as a template for repair, making it higher fidelity. 
While a homologous chromosome can act as the template for HR, a sister 
chromatid is the preferred template for recombination,(87) thereby preventing 
loss of heterozygosity.  
In order to proceed with HR, following the formation of a DNA DSB the 
broken strand must undergo long-range 5’-3’ end resection to generate a ssDNA 
overhang. In human cells, end resection is regulated by the MRN complex 
(MRE11, RAD50, NBS1), CtIP and BLM.  CtIP and MRN initiate resection, but 
are not responsible for the long-range resection necessary to promote 
downstream HR pathways(85, 88). Following the initiation of resection, BLM 
helicase cooperates with the nucleases EXO1 and DNA2 to promote long-range 
resection. (88–91)  Long-range resection creates an extended 3’-OH ssDNA 
overhang, which is the initiating structure for homology-directed repair.  (Fig 1.3) 
During resection, RPA coats the ssDNA, promoting stability of the 3’ 
overhang and preventing the formation secondary structures.(91–93) A 
recombinase protein, such as RAD51, replaces RPA, thus forming a RAD51-
ssDNA nucleofilament capable of performing a homology search to identify a 
template for repair. Once a region of homology has been identified, the 
nucleofilament invades the template DNA, forming a triple stranded paranemic 
structure.(94, 95) This unstable paranemic structure is converted into a stable 
plectonemic DNA joint when the homologous template is melted, allowing the 3’-




second strand on the template DNA, creating a mature displacement loop (D-
loop).(96, 97) The stability of the RAD51 nucleofilament prior to strand invasion, 
along with the formation of mature plectonemic D-loops, is regulated by the DNA 
translocase, RAD54.(96–103) RAD54 is a conserved DNA repair protein that 
belongs to the RAD52 epistasis group, composed of proteins known to regulate 
HR.(99, 104–108) The ATPase-dependent DNA translocase activity of RAD54 
has been hypothesized to aid in the RAD51-dependent homology search by 
acting as the motor that facilitates movement of the RAD51 nucleofilament along 
candidate template DNA molecules until homology is detected.(106, 107, 109) 
RAD54’s translocase activity has also been shown to cause DNA supercoiling 
and regulate nucleosome position, both of which may play a role in making 
template DNA molecules more permissive to strand invasion.(105, 110) 
Additionally, RAD54 has been shown to play a critical role in the conversion of 
paranemic joints to plectonemic D-loops, a necessary step for the recruitment of 
DNA polymerases and subsequent elongation of the broken DNA strand.(96, 
101) (Fig 1.3)  
For repair of a two-ended DNA DSB, the D-loop is thought to promote 
second end capture to create a double Holliday junction (dHJ).(111, 112) To do 
this, the displaced single stranded template DNA in the D-loop anneals with the 
resected ssDNA on the other side of the DSB, such that both sides of the DSB 
are now engaged in HR. (Fig 1.3) Second-end capture and formation of the dHJ 




double Holliday junctions are processed to the two DNA strands involved in 
recombination. Double Holliday junctions can be dissolved by complexes such as 
BTR (BLM, TOP3A, RMI1/2) to generate non-crossover products. BLM is thought 
to promote convergent branch migration, followed by decatenation of the dHJ by 
TOP3A.(115–117) Alternatively, dHJs can be processed by resolvase enzymes, 
such as structure specific endonucleases SLX1-SLX4, MUS81-EME1 and GEN1, 
to generate either crossover or non-crossover products. GEN1 is the canonical 
Holliday junction resolvase, and interestingly is excluded from the nucleus until 
mitosis, indicating that dissolution is the preferred method of dHJ processing and 
cleavage is a backup mechanism to prevent the mitotic defects associated with 
persistent recombination intermediates.(116, 118) While SLX1-SLX4 and 
MUS81-EME1 do not demonstrate efficient nuclease activity on intact dHJs, 
through their coordinated activity they can promote the resolution of dHJs, with 
SLX1-SLX4 nicking the dHJ, thereby promoting resolution by MUS81-
EME1.(119) Loss of redundant dHJ processing pathways leads chromosomal 
instability, exemplified by the accumulation of ultra-fine anaphase bridges, 
lagging chromosomes, and micronuclei.(115, 116, 119, 120) 
Replication fork collapse generates a single-ended DSB, and therefore 
utilizes a specific repair pathway called BIR. BIR is a conserved DNA repair 
pathway, though it has been studied most extensively in DNA replication and 
repair in yeast. In yeast and mammalian cells, following resection BIR has been 




mechanisms of strand invasion.(121–123) RAD51-independent D-loop formation 
during BIR is thought to rely on RAD52. Like RAD51, mammalian RAD52 is 
capable of forming nucleofilaments on ssDNA, promoting annealing between 
homologous DNA strands, thereby facilitating D-loop formation.(124) Recent 
studies have demonstrated that RAD52 plays an important role in homologous 
strand annealing during BIR following replication fork collapse,(122, 125–127) 
suggesting that D-loop formation during BIR may occur through RAD51- or 
RAD52- dependent pathways. Following the formation of the D-loop, repair by 
BIR relies on the recruitment of DNA replication machinery, including the DNA 
binding clamp, PCNA, and the POLD3 subunit of Polδ.(128) The D-loop is 
migrated down the template DNA through branch migration, promoting extended 
DNA synthesis events by Polδ.(129, 130) DNA synthesis during BIR is 
conservative and asynchronous, meaning that a traditional replication fork is not 
formed. Instead, the D-loop migration allows leading strand synthesis and 
extension to occur on the invading DNA strand, leading to the accumulation of 
ssDNA. (Figure 1.3) The second strand is filled in separately using the newly 
synthesized DNA as a template.(130, 131) Interruption of D-loop migration 
initiates cleavage events, leading to the formation of crossover or half crossover 
products depending on the cleavage site.  
While genome replication during S-phase is known for its high fidelity, BIR 
is fairly inaccurate and mutagenic. Polδ generates a high degree of frameshift 




DNA damage.(132, 133) Furthermore, while proofreading and mismatch repair 
mechanisms are active during BIR, they are far less efficient than during S-
phase. Many of the mutations caused by Polδ during BIR are consistent with 
polymerase slippage.(121, 132) This is of particular interest because repetitive 
regions of the genome, such as the telomere, are already prone to polymerase 
slippage, indicating that the mutagenic nature of BIR may be further enhanced at 
telomeric DNA.  In addition to the mutagenic nature of the POLD3, BIR also 
leads to loss of heterozygosity and frequent genome rearrangements, making it 
an error-prone repair mechanism of HR.  
Replication stress at the telomeres 
Telomeres are essential to the maintenance of genome stability, however, the 
structure and inherent fragility of mammalian telomeres pose a challenge to DNA 
replication, making them prone to replication stress and DNA damage. Studies in 
yeast demonstrate that replication forks paused on telomeric DNA, both at the 
terminal ends of the chromosome and when telomeric repeats were artificially 
embedded in other regions of the genome.(134–136) Moreover, under low levels 
of replication stress, telomeric DNA showed signs of fragility and broken DNA, 
suggesting that telomeres, along with other repetitive regions of the genome, 
resemble CFS.(136) While faithful telomere replication is required to maintain 
genome stability, there are several inherent sources of replication stress 








Figure 1.4 – Sources of replication stress at telomeres. 
Several features of the telomere make this region of the genome prone to replication stress. 
Telomeres are repetitive sequences, which inherently cause polymerase stalling and slipping, 
and as a result can cause replication stress and lead to mutagenesis.  Telomere can also accrue 
DNA damage following oxidative stress, which leads to the formation of oxidized guanine 
residues (8-oxo-G). The 8-oxo-G residue decreases shelterin binding and promotes telomere 
instability and can be resolved either by repairing the DNA lesion or utilizing damage tolerance 
pathways, such as trans lesion synthesis.  Secondary structures including both G4s and the T-
loops (not shown) block the replicative machinery, and are resolved by either helicases (RTEL1, 
BLM, and WRN) or nucleases (SLX4, TZAP).  Finally, the transcription of TERRA at telomeres 
generates R-loops that can also block the replication machinery and are removed by nucleolytic 
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the telomeric sequence, along with the proclivity for secondary structures and 
propensity for collisions with the transcriptional program. (Fig 1.4) 
Shelterin 
Shelterin binding was initially thought to be a source of replication stress, 
acting as a roadblock to the replisome.(137) However, TRF1, TRF2 and POT1 
have been shown to promote telomere replication, prevent fork stalling, and 
protect against telomere fragility. Shelterin may accomplish this by facilitating the 
resolution of common structures found at the telomeres that cause replication 
stress, including G4s and the T-loop.(136, 138–140) This means that changes to 
shelterin binding capacity, for instance, by increasing the prevalence of non-
canonical telomeric repeats, can lead to increased replication stress and 
telomere fragility.(136, 141) 
Repetitive G-rich sequence 
Repetitive regions of the genome, including but not limited to telomeric 
DNA, make up half of the human genome and cause inherent challenges to DNA 
replication. In addition to DNA polymerase slipping, which can cause expansion 
of repetitive regions of DNA(142) and/or introduce DNA mismatches,(143) the 
replisome is also prone to stalling,(144) highlighting an inherent challenge to 
replicating repetitive regions of DNA, such as telomeres. In addition to being 
repetitive, telomeric DNA is also rich in guanine nucleotides. Guanine residues 




Chronic oxidative stress can lead to telomere dysfunction, attrition, and ultimately 
cellular senescence.(145, 146)  
The G-rich sequence of the telomere is also prone to forming G-
quadruplex (G4) secondary structures that are stabilized by Hoogsteen pairing. 
(147, 148) The G4 structures are generated by four guanine residues that 
assemble into a planar quartet, which can then stack on top of one another to 
create an extremely stable nucleic acid structure.(149, 150) Pharmacological 
stabilization of G4s impairs replication fork progression in the telomere, inducing 
replication stress and increasing telomere fragility.(151–153) These data 
highlight the need to resolve telomeric G4s to ensure faithful replication of the 
telomeric DNA.(153) In vitro G4s can be unwound by the RecQ family helicases 
BLM and WRN.(154) Human cells lacking WRN require extended time to 
complete S-phase,(155) and have specific defects in telomere replication leading 
to telomere loss and instability.(156, 157) TRF2 interacts with WRN helicase and 
stimulates helicase activity,(158) suggesting that WRN may be recruited to the 
telomere to unwind structures like G4s.  Human cells lacking BLM helicase show 
evidence of telomere fragility that is epistatic with loss of TRF1,(136) suggesting 
that BLM and TRF1 functions are coordinated to unwind secondary structures 
during lagging strand DNA synthesis at the telomeres.(159) In addition to BLM 
and WRN, the regulator of telomere length (RTEL1) helicase has been implicated 
in resolution of secondary structures at telomeres, including G4s.(160) RTEL1 




interacting protein (PIP) box domain,(161) and RTEL1 depletion causes additive 
telomere fragility when combined with BLM depletion, suggesting multiple, non-
overlapping mechanisms for resolution of G4s at telomeres by RTEL1 and 
BLM.(160, 161) There are several other helicases and enzymes that have been 
identified to possess G4 unwinding activity and are also known to associate with 
mammalian telomeres, including PIF1, FANCJ and the CST complex. However 
the exact functions and mechanisms of these helicases at mammalian telomeres 
are still emerging.(162–170) 
T-loop structure 
Another structure found at the telomere that can be an impediment to 
completing replication is the T-loop. The T-loop serves an important function in 
protecting telomere ends, but can also act as a source of replication stress, 
preventing the replisome from gaining access to the terminal end of the 
chromosome. In addition to its role in G4 resolution, RTEL1 supports telomere 
replication by disassembling the T-loop structure.(160, 161) TRF2 recruits 
RTEL1 specifically to the telomeres to promote T-loop resolution during S-
phase,(171) separate from the PCNA mediated recruitment of RTEL1 to resolve 
G4 structures. In addition, both BLM and WRN helicases have been suggested 
to unwind the T-loop structure in vitro.(158) In the absence of RTEL1, T-loops 
are cleaved by the SLX4-dependent nucleases, which creates extrachromosomal 
telomeric repeats (ECTRs) and causes telomere shortening, thereby expediting 




was also shown to cleave T-loop structures from excessively long 
telomeres.(172, 173) Long telomeres are particularly susceptible to replication 
stress,(174) indicating that cells maintain mechanisms to trim these telomeres in 
order to promote successful telomere replication. However, whether TZAP 
functions to mitigate replication stress at telomeric DNA has not been 
investigated. 
TERRA R-loops 
The telomere is transcribed into a long non-coding RNA called 
TERRA.(175, 176) In mammalian cells, TERRA is cell cycle regulated and plays 
a role in reloading the shelterin component POT1 following replication, ensuring 
proper end protection of telomeres.(63, 177–179) Once transcribed, a fraction of 
TERRA is chromatin bound,(178) and can hybridize with DNA (175, 180–182) 
forming a triple stranded DNA:RNA hybrid structure called an R-loop.(183, 184) 
R-loops have many functions within the genome, both beneficial and 
deleterious.(183, 185) They can pose an obstacle to the DNA replication 
machinery, inducing replication fork stalling and collapse, and ultimately leading 
to DNA DSBs formation and homology directed repair through BIR.(183, 186–
188) Induction of TERRA transcription leads to an increase in telomere fragility in 
mammalian cells,(180) indicating that TERRA R-loops may contribute to 





Section 3: Mechanisms of telomere maintenance 
Telomere integrity is crucial for maintaining genome stability and 
replicative potential. In addition to the inherent replication stress and endogenous 
insults experienced by the telomeres, telomeric DNA degrades naturally over 
successive cell divisions due to the nature of DNA replication, as previously 
described.(13, 14) During DNA replication, two bidirectional replication forks are 
created that move away from the origin as the CMG complex unwinds dsDNA, 
allowing the replisome to copy each strand of DNA.(40) DNA replication is 
semiconservative, and can only proceed in the 5’ – 3’ direction, which leads to a 
difference in how leading strand versus lagging strand DNA is synthesized. Pol ε 
synthesizes the leading strand of DNA continuously as the replisome travels. 
However, Pol δ synthesizes discontinuous fragments of DNA that are extended 
from RNA primers.(40) To complete lagging strand synthesis, RNA primers are 
removed and filled in with DNA nucleotides.  
At telomeres, much like the rest of the genome, leading strand synthesis is 
processive and therefore continues to the terminal end of the chromosome, 
creating a blunt end. The telomeric DNA generated by leading strand synthesis 
must then be processed by nucleases, including Apollo and EXO1, to create the 
characteristic telomeric 3’ overhang that facilitates T-loop formation. Likewise, 
the newly synthesized lagging strand is also processed to create the mature 3’ 
G-rich overhangs characteristic of telomeres. (189–191) However, due to the 




lagging strand cannot be extended through the terminal end of the telomere. 
When the terminal RNA primer is degraded it leaves a gap at the end of the 
chromosome that cannot be filled in, ultimately leading to telomere shortening. 
This limitation of DNA replication in eukaryotic cells is referred to as the ‘end-
replication problem’.(10, 192) (Figure 1.5A) 
The persistent erosion of telomeric DNA due to the end-replication 
problem compromises the end protection function of the telomere and ultimately 
threatens genome stability. When the telomeric DNA shortens to a critical length, 
the telomere end initiates a DNA damage response that triggers the exit from the 
cell cycle into a metabolically active, but non-dividing state called cellular 
senescence.(10) This means that somatic cells are only capable of undergoing a 
finite number of cell divisions, called the Hayflick limit.(193, 194) The Hayflick 
limit restricts the replicative capacity of individual cells, thereby acting as a 
mechanism to suppress the formation of tumors.  
During oncogenic transformation, cells frequently lose proper function of 
the DNA damage response and checkpoint pathways that should be activated by 
shortened telomeres, thus preventing induction of senescence and instead 
allowing these cells to continue dividing.(195) The telomeres continue eroding 
until they are no longer able to repress NHEJ, at which point the cells enter a 
state of massive genomic instability called crisis.(15, 16, 196) (Fig 1.5B) Crisis is 
marked by chromosomal breakage and subsequent fusions, leading to large-





 Figure 1.5 – The end replication problem and result of telomere shortening 
A) When DNA is replicated, leading strand synthesis proceeds continuously.  Lagging strand 
synthesis is discontinuous, with fragments of Okazaki fragments being synthesized off of 
RNA primers.  The RNA primers are removed and filled in with DNA nucleotides, leaving a 
gap at the terminal end of the chromosome.  
B) Due to the end replication problem, telomeric DNA is lost every time the cell divides, 
manifesting as a shortening of telomeric DNA. Once the telomeres are completely eroded 
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activating a mechanism to maintain telomere length, thereby acquiring replicative 
immortality, considered one of the hallmark traits of cancer cells.(195) It is 
estimated that 90% of cancers achieve replicative immortality by reactivating the 
enzyme telomerase, which is normally active during development. Telomerase is 
minimally composed of a reverse transcriptase (TERT) and internal RNA 
component (TERC), and functions by progressively adding TTAGGG repeats 
onto the ends of telomeres.(197, 198) The remaining 10% of cancers maintain 
telomere length in the absence of telomerase by activating a recombination-
based telomere elongation mechanism called the Alternative Lengthening of 
Telomeres (ALT) pathway.(199)  
Mechanisms of telomere elongation are an attractive target for therapeutic 
intervention in cancer because most normal somatic cells lack telomere 
maintenance mechanisms. Telomerase inhibitors have been developed, 
including an anti-sense oligonucleotide that binds to TERC, called Imetelstat, 
While showing some success in thrombocytopenia, imetelstat has shown limited 
efficacy in clinical trials to treat cancer due to hematological and liver 
toxicities.(200, 201) To induce cytotoxicity in the cancer cells via telomere 
shortening, patients would need to undergo prolonged treatment with telomerase 
inhibitors, allowing for progressive telomere attrition until the chromosomes are 
uncapped, and cancer cells enter into crisis. To date, no targeted therapies have 




mechanisms underlying ALT telomere elongation could help identify therapeutic 
targets and potentially improve prognosis in patients with ALT positive cancers.   
 
Section 4: Alternative Lengthening of Telomeres 
The identification of cancer cells that maintain telomere length in the 
absence of telomerase activity led to the first description of the ALT 
pathway.(202) While ALT activity is not detected in normal non-neoplastic 
tissue,(199) the ALT pathway is activated in 5-10% of all cancers, with its 
prevalence varying by cancer subtype. ALT activity has been identified in a wide 
variety of tumor types, though it tends to be most prevalent in cancers of 
mesenchymal origin, such as sarcomas and neuroendocrine tumors.(199, 203, 
204) For example, ALT activity has been reported in ~60% of osteosarcoma 
cases and ~60% of pancreatic neuroendocrine tumors but only ~5% of breast 
cancers, which tend to be carcinomas. (199, 203, 204) Reporting of ALT status in 
tumors is confounded by the fact that ALT activity cannot be accurately predicted 
from any single genetic marker or expression pattern, and instead relies on 
phenotypic measures that are limited in their experimental throughput.   
Cells with an active ALT mechanism are characterized by a number of 
unique cellular phenotypes.(205) These phenotypes have not only served as 
surrogates for ALT activity, but have also been instrumental in developing our 
understanding of the ALT mechanism. One of the first observations made in ALT 
cells was that telomeric DNA in ALT cells is incredibly dynamic, constantly 




heterogeneity in telomere length was one of the first indications that telomeres in 
ALT cells might be elongated by a recombination-based mechanism.(202) Later 
experiments confirmed the role of recombination in maintaining ALT telomeres by 
demonstrating that a DNA tag incorporated into a single telomere was copied into 
other chromosome ends,(206) highlighting the role of homology-directed repair in 
promoting telomere elongation.  
These findings were later supported by studies demonstrating that the 
telomeres in ALT cells are recruited into nuclear foci, that in addition to the 
promyelocytic leukemia (PML) protein, contain a number of recombination and 
repair factors, including, but not limited to, RAD51, RAD52, RPA, BLM, and 
WRN.(207–209) These ALT-associated PML bodies (APBs) are also believed to 
be associated with the ECTR-containing DNA generated in ALT cells. Given that 
APBs contain clustered telomeric DNA along with many DNA damage repair 
proteins, they are often thought to be platforms for recombination or active sites 
of ALT telomere elongation. 
ALT cells also contain elevated quantities of ECTR DNA, in both linear 
and circular forms.(210, 211) A subset of these ECTR are likely generated as a 
byproduct of recombination, and they may also perpetuate the ALT phenotype by 
functioning as a template for elongation.(210, 211) Induced damage or 
exacerbated replication stress at ALT telomeres increases the abundance of a 
subset of ECTR that are C-rich and partially single stranded (C-circles).(123, 




of ALT activity.(213) It was recently demonstrated that elongation of ALT 
telomeres happens preferentially at lagging strand overhangs, suggesting that C-
circles are produced as a replication dependent byproduct of recombination.(214) 
Together, these cellular phenotypes demonstrate the ability of ALT cells to utilize 
normal DNA repair machinery for telomere elongation through recombination and 
highlight the importance of chronic DNA damage at ALT telomeres in maintaining 
a sustained recombinogenic state.  
Genetics of ALT 
Genetic defects and mutations in the chromatin remodeling complex 
composed of ATRX (α-thalassemia/mental retardation syndrome X-linked), 
DAXX (death-domain associated protein) and histone variant H3.3 are highly 
correlated with the presence of ALT activity in tumors.(203, 215) ATRX is a 
chromatin-remodeling enzyme that is part of the SWI/SNF2 family. In conjunction 
with DAXX, ATRX functions to deposit histone variant H3.3 into heterochromatic 
regions of the genome, including the telomere. Loss of ATRX in non-ALT cells 
renders cells susceptible to replication stress, especially G4 stabilizing agents, 
leading to replication fork stalling and collapse.(216–218) Ectopic expression of 
ATRX in ALT cells causes a decrease in ALT activity and ALT associated 
phenotypes.(219, 220) Moreover, the suppression of ALT activity by expression 
of ATRX relies on functional DAXX, suggesting that ATRX and DAXX together 
suppress recombination at ALT telomeres, though the mechanism of ALT 




loss of ATRX or DAXX alone has not been demonstrated to fully activate the ALT 
mechanism. It is suggested that the loss of ATRX or DAXX leads to progressive 
telomere dysfunction, potentially leading to the activation of ALT eventually.(220, 
221) Therefore, ATRX/DAXX dysfunction is not sufficient to cause ALT activity. 
Additionally, across several studies there is data demonstrating that a 
measureable subset of ALT positive tumors have functional ATRX and DAXX, 
(203, 215) indicating that there may be other genetic abnormalities underlying 
activation of the ALT pathway.  
The DNA annealing helicase SMARCAL1 (SWI/SNF Related, Matrix 
Associated, Actin Dependent Regulator of Chromatin, Subfamily A-like 1) is one 
of the most enriched proteins found at sites of replication stress (82) and 
functions to promote replication restart and/or repair by mediating replication fork 
reversal.(222–225) More recently it was demonstrated that SMARCAL1 functions 
to remodel stalled replication forks at telomeric DNA, and is significantly enriched 
at ALT telomeres. (212, 226) A recent study performed in depth genetic analysis 
of glioblastomas that had wild-type ATRX and lacked activating mutations in the 
TERT promoter. In this cohort of glioblastomas, which lacks a genetically defined 
telomere maintenance mechanism, a subset of tumors contained somatic loss-of-
function mutations in the SMARCAL1 gene and exhibited ALT phenotypes. (227) 
Given the role SMARCAL1 plays in managing replication stress at the telomeres, 
this suggests that cells lacking SMARCAL1 may be prone to breakage and 




SMARCAL1 in SMARCAL1 deficient ALT cell lines represses ALT activity. In ALT 
cells with wild-type SMARCAL1, SMARCAL1 functions to maintain a balance 
between telomere stability and recombination.(212) SMARCAL1 helps to 
maintain tolerable levels of replication stress at ALT telomeres, enough to 
engage telomere elongation through BIR, but no so much as to overwhelm the 
DNA repair machinery and induce cell death. The identification of SMARCAL1 as 
a genetic repressor of ALT suggests that ALT activation is a multi-genic 
phenotype, and that different tumors may arrive at an active ALT pathway 
through different means. Like ATRX and DAXX, short-term loss of SMARCAL1 
alone seems insufficient to induce ALT,(226) indicating that loss of ATRX, DAXX 
or SMARCAL1 may release repression of the ALT pathway, but a subsequent 
activating event or series of events is still required. ATRX, DAXX and 
SMARCAL1 mutations together can account for the loss of repression in many, 
but not all ALT tumors, suggesting that there may be additional somatic genetic 
mutations or abnormalities contributing to ALT. The work described in Chapter 2 
characterizes novel genetic abnormalities in ALT positive osteosarcoma tumors, 
further elucidating the genetics underlying ALT activation. 
Specific sources of replication stress at ALT telomeres 
While the initiating events for ALT are not fully understood, the 
recombinogenic state at ALT telomeres is maintained by chronic replication 
stress at the telomeres leading to high levels of endogenous DNA damage. 








Figure 1.6 – Causes of chronic replication stress found at ALT telomeres.   
ALT telomeres have deregulated TERRA expression, incorporation of variant repeats, altered 
chromatin environments due to frequent loss of ATRX/DAXX/H3.3 and can be excessively long 
(not shown), compounding the replication stress normally present at telomeres.   
  
  




























the general difficulty associated with telomere replication, several features of ALT 
telomeres make them even more susceptible replication stress (Fig 1.6). 
Telomere length and sequence 
Long telomeres are inherently more susceptible to replication stress.(174, 
228, 229) Although telomere length is variable across cells and/or tissue, ALT 
telomeres can reach up to 50 kilobases in length,(202) which is 3-5 times longer 
than the typical telomere length found in human cells, therefore making ALT 
telomeres predisposed to frequent replication fork stalling. In addition, ALT 
telomeres contain both canonical and degenerate, or variant, repeats. Variant 
repeats are non-canonical telomeric sequences, including TCAGGG (C-type) or 
TGAGGG (G-type), interspersed within the canonical TTAGGG telomeric 
repeats.(141, 230, 231) These variant repeats spread stochastically throughout 
telomeres in ALT cells through homology directed repair. Variant repeats bind the 
shelterin component TRF2 with nearly 6-fold less affinity than canonical 
repeats,(141) contributing to telomere deprotection and, ultimately, inducing 
telomeric DNA damage. This conclusion was supported by studies demonstrating 
that the introduction of variant repeats leads to decreased TRF2 binding, and an 
elevation in telomere dysfunction-induced foci (TIFs).(141) This moderate 
deprotection increases replication stress, as measured by an increase in 
telomere fragility, and contributes to DNA damage at ALT telomeres.(136, 141, 
159, 230) Variant repeats bind nuclear receptors COUP-TF2 and TF4 with high 




deacetylation (NuRD) complex, decompacting chromatin at ALT telomeres.(232) 
The combination of decreased shelterin binding and decompacted chromatin at 
ALT telomeres creates an environment that perpetuates chronic replication 
stress and recombination. Although decreased shelterin binding is a 
consequence of the incorporation of variant repeats, it does not appear sufficient 
to activate ALT activity. Incorporation of variant repeats in a telomerase positive 
cell line causes some ALT-associated characteristics, but it does not cause 
detectable recombination events between telomeres.(141) 
Altered chromatin environment 
The chromatin environment at ALT telomeres has also been hypothesized 
to contribute to replication stress and telomere fragility in ALT cells.  Given that 
ATRX is a heterochromatin binding protein, it has long been hypothesized that 
the loss of ATRX or DAXX that is frequently associated with ALT tumors 
compromises chromatin compaction, creating a less heterochromatic 
environment at ALT telomeres that is more permissive to recombination.(233, 
234) Conversely, a recent study demonstrated that a decrease in 
heterochromatin formation at the telomeres in fact inhibits ALT phenotypes, 
indicating a heterochromatic environment may stimulate ALT activity rather than 
inhibiting it.(235) While the consequences of the altered chromatin environment 
at ALT telomeres are still under investigation, it is reasonable to conclude that 
alterations in histone deposition, organization, and modification, are likely to lead 




replication must proceed within the chromatin environment. In support of this, 
loss of the histone chaperone ASF1 (anti-silencing factor 1) in mammalian cells, 
which promotes histone transfer during replication, leads to the rapid induction of 
ALT phenotypes.(64). This observation highlights that changes in chromatin 
structure at ALT telomeres can contribute to the replication stress and 
recombination underlying ALT activity. 
ATRX inactivation and changes in the chromatin environment of ALT 
telomeres have also been linked with the deregulation of the telomere transcript, 
TERRA.(63, 236) TERRA is cell cycle regulated, with levels decreasing during 
late S-phase before reaccumulating during the next cell cycle.(177–179) The cell 
cycle regulation of TERRA promotes a switch between telomere replication and 
end-protection by facilitating the exchange between RPA and POT1 at the single 
stranded region of the telomere.(177) The decrease and subsequent 
reaccumulation of TERRA promotes the displacement of RPA following S-phase, 
helping to reload POT1 onto telomeres to facilitate telomere end-protection and 
suppress the DNA damage response. When cell cycle regulation of TERRA is 
lost, RPA remains bound to single stranded telomeric DNA.(63) RPA coated 
ssDNA recruits and activates ATR,(57) and the RAD51 recombinase that initiates 
HR,(123)  thus promoting a DNA damage response and recombinogenic state at 






High levels of TERRA 
TERRA levels are typically increased in ALT cells as compared to 
telomerase positive cells. Cell cycle regulation of TERRA is lost in at least a 
subset of ALT cancers.(63, 234, 237) Loss of TERRA cell cycle regulation has 
the potential to induce replication stress at ALT telomeres by increasing telomeric 
R-loops, and altering telomere end protection. In support of this hypothesis, 
TERRA R-loops have been demonstrated at mammalian and yeast 
telomeres,(180–182, 237) and deregulation of TERRA leads to an increase in R-
loop formation at telomeric DNA.(180) In ALT cells, overexpression of RNAseH1, 
which degrades R-loops, causes a decrease in TERRA R-loop formation and a 
subsequent decrease in recombination at ALT telomeres.(180) TERRA 
transcription is increased in ALT cells,(234) likely resulting in increased level of 
telomeric R-loops. Unresolved TERRA R-loops lead to an increase in replication 
stress and an increase in recombination at ALT telomeres.(180–182) While 
RNaseH1 is known to degrade TERRA R-loops, it is suggested that other 
enzymes, such as SETX or FANCM may promote dissolution of R-loops, 
including those formed at telomeres.(238–240) It would be interesting to 
determine whether there are any defects in R-loop resolution specific to ALT 
cells. 
DNA damage response at ALT telomeres 
ALT telomeres experience high levels of spontaneous DNA damage and 




lines,(152) which is thought to be a result of chronic replication stress. ALT 
telomeres show length independent signs of dysfunction, measured by the 
colocalization of telomeres with 53BP1 or γ-H2AX in telomere dysfunction 
induced foci (TIFs).(241) Spontaneous TIFs are found throughout the cell cycle in 
unperturbed ALT cells, including during metaphase. Despite having signs of 
active DNA damage response at the telomeres, ALT cells are still able to repress 
end-to-end fusions. Therefore, the elevated TIFs in ALT cells may represent an 
intermediate level of telomere deprotection that is permissive to recombination 
while being distinct from full telomere uncapping or crisis. It is hypothesized that 
this intermediate level of deprotection helps to recruit DNA repair proteins to ALT 
telomeres to facilitate recombination. ALT telomeres frequently cluster in APBs, 
which also contain a host of HR proteins, including RAD51, RAD52, RPA, MRN, 
BLM and SLX4.(205, 242) These HR proteins are not only found at ALT 
telomeres, but are in fact essential for survival in telomerase-negative yeast(243, 
244) and for successful telomere maintenance in ALT cells. 
Supporting a role for replication stress as the cause of DNA damage at 
ALT telomeres, ALT cells also show an accumulation of RPA coated ssDNA at 
telomeres, a marker of replication stress caused by fork stalling.(62–64) The 
persistent RPA-coated ssDNA at ALT telomeres also functions to activate 
ATR.(53, 57–60) Furthermore, recent studies have demonstrated that ALT cells 
require ATR to promote telomere elongation and subsequently maintain ALT 




ALT activity, chromosomal fragmentation, and eventually induces apoptosis,(63) 
suggesting that ATR inhibitors have potential as a targeted therapeutic for ALT 
positive cancers.  
Break-induced replication at ALT telomeres 
ALT cells have long been known to utilize HR for telomere elongation. 
More specifically, recent studies demonstrate that ALT cells promotes telomere 
elongation through a process resembling BIR,(73, 122, 152, 245) a specific form 
of HR that is important for repair of collapsed replication forks.(80, 81, 246) 
Irreversibly stalled replication forks at ALT telomeres collapse into single ended 
DNA DSBs, which engage BIR for repair. This repair process leads to extension 
of broken telomere ends and de novo synthesis of telomeric DNA, resulting in net 
telomere elongation.  
ALT cells telomeres elongate through a BIR-like mechanism that can be 
divided into three main steps 1) the presynaptic resection of the DSB and 
formation of a nucleofilament that is capable of strand invasion, 2) synapsis of 
the broken DNA strand with a homologous template to form of a mature D-loop, 
and 3) post-synaptic dissolution or resolution of the D-loop structure. Although it 
is still not well understood what initiates ALT activity, the recombinogenic state of 
ALT telomeres is maintained through chronic replication stress and DSB 





Much like the BIR genome wide, following the formation of a single ended 
DSB at an ALT telomere, the broken end is resected to created a 3’ ssDNA 
overhang. It was recently demonstrated that BLM is a crucial regulator of long-
range resection at ALT telomeres, independent of its role in the BTR 
dissolvasome.(247) Following resection, a recombinase protein, such as RAD51 
or RAD52, binds the single stranded telomeric DNA to form a ssDNA 
nucleofilament. RAD54, an ATP-dependent translocase, stabilizes RAD51 
nucleofilaments and promotes strand invasion, though has no known interactions 
with RAD52. (98, 103, 107, 108) The pre-synaptic homology search and strand 
invasion at ALT telomeres has been shown to be primarily RAD51-independent, 
and is instead thought to rely on RAD52. (58, 122, 123, 152, 248) Recent 
evidence also suggests that strand invasion at ALT telomeres may also occur 
through a yet uncharacterized RAD52-independent mechanism.(248, 249) The 
nucleofilament facilitates search and capture of a homologous template, which 
can be a sister chromatid, another telomere, or ECTRs. Once a homologous 
template is identified, the nucleofilament promotes strand invasion, leading to the 
synapsis of stable, plectonemic D-loop structure.  
Synapsis of a fully interwound, plectonemic D-loop structure is important 
for the recruitment of DNA synthesis machinery.(96, 101) During HR genome-
wide, D-loop synapsis requires RAD54 to promote the base pairing between the 
invading strand and template DNA,(97, 98, 101, 105) however the role of RAD54 




PCNA, DNA polymerase η (Polη),(169) and the POLD3 subunit of DNA Polδ (the 
putative BIR polymerase) to facilitate DNA damage repair and ultimately, the 
elongation of telomeric DNA.(122) (Fig 1.3)  
Following synapsis, the D-loops formed at ALT telomeres can be resolved 
through two different mechanisms (Fig 1.3). Intermediates can be cleaved by the 
SMX (SLX1-4, MUS81-EME1, XPF-ERRC1) resolvasome, leading to crossover 
events, called telomere sister chromatid exchange (T-SCE). The formation of T-
SCE does not require DNA polymerases, nor any DNA synthesis. This result 
demonstrates that T-SCE, while elevated in ALT positive tumors,(250) do not 
necessarily represent telomere elongation events.(73) Alternatively, the D-loop 
can be migrated down the template strand through branch migration, leading to 
extension of the invading DNA strand by Polη and Polδ followed by BLM-
dependent dissolution of the DNA joint. It is hypothesized that migration of the D-
loop could proceed all the way to terminal end of the homologous template. 
Resolution of recombination intermediates through branch migration promotes 
extended synthesis of telomeric DNA, promoting net telomere elongation.(73) 
Given that ALT telomeres present challenges to replication machinery, it is also 
possible that BIR machinery could stall while extending ALT telomeres. Stalling 
of a D-loop during branch migration could lead to a combined phenotype where 
there is a branch migration and limited DNA synthesis, followed by a cleavage 




formed at ALT telomeres, illustrating a role for RAD54 in promoting branch 
migration of D-loops. 
ALT telomeres can be repaired through BIR either during interphase, by 
engaging break-induced telomere synthesis (BiTS), or during mitosis, by 
engaging mitotic DNA synthesis (MiDAS).(122, 152) The BiTS and MiDAS 
pathways converge, both relying on the POLD3 subunit Polδ for elongation 
events, indicating that both are a form of BIR and may differ primarily based on 
the phase of the cell cycle in which they are engaged. Telomerase null yeast also 
maintain telomere length by two different pathways, utilized by either Type I 
survivors or Type II survivors, which represent RAD51-dependent and RAD51-
independent telomere recombination, respectively.(243, 244) Both Type I and 
Type II survivors in yeast rely on RAD52 for survival.(243) While there are some 
parallels between Type I survivors and BiTS and between Type II survivors and 
MiDAS, (122, 123) these comparisons are confounded by the fact that the 
functions of RAD52 are not fully conserved between yeast and mammalian cells. 
In mammalian cells, RAD52-dependent BIR is thought to promote the bulk of 
recombination at ALT telomeres, but is not necessary for survival.(152, 248, 251) 
Furthermore, unlike the telomerase null yeast survivors, ALT positive cancers 
cells can proliferate in the absence of both RAD51 and RAD52,(248) 
demonstrating that there are additional redundant pathways that manage 





Section 5: Concluding remarks  
 The early studies of ALT telomeres suggested that ALT-positive cancer 
cells maintain telomere length using homology directed repair. The ALT 
mechanism has since been refined to specifically resemble break-induced 
replication.  BIR at ALT telomeres can be divided into three important stages 1) 
The formation of DNA damage and resection of the damaged DNA to form a 
structure capable of performing a homology search and strand invasion (Pre-
synapsis). It is not currently clear what the initiating events are to allow ALT 
activity, however DNA damage at ALT telomeres appears to be the result of 
unresolved replication stress. 2) Strand invasion event and the formation of a 
plectonemic D-loop structure (Synapsis). RAD51 and RAD52 are both involved in 
strand invasion events genome-wide, though ALT relies more heavily on RAD52. 
There may be additional RAD51 and RAD52 independent mechanisms that are 
not yet described. And 3) the D-loop structure must be resolved through 
dissolution, cleavage, or some combination of the two (Post-synapsis). During 
post-synaptic processing of the D-loop, telomere extension and elongation 
events can only occur if the D-loop is migrated down the template DNA. 
Alternatively, during post-synaptic processing the D-loop can be cleaved, either 
before any branch migration or to rescue a stalled D-loop, leading to T-SCE 
crossover products. Post-synaptic processing of the D-loop is important both to 




unresolved recombination intermediates that can cause genome instability as the 
cells progresses through mitosis.  
 The ALT pathway provides an attractive therapeutic target. In addition to 
being unique to cancer cells, many of the cancers that have a high prevalence of 
ALT, such as osteosarcoma, have no targeted therapies currently available. 
Successful therapeutic intervention targeting the ALT pathway requires both a 
clear understanding of the ALT mechanism to be able to identify druggable 
targets, and the ability to easily identify tumors that utilize the ALT pathway.   
Through this body of work, we sought to further elucidate the mechanisms 
of ALT mediated telomere elongation through two main aims.  Aim 1 – to further 
define the genetic mutations and alterations underlying ALT activation. Aim 2 – to 
define the mechanism of ALT by investigating the role of RAD54 in ALT mediated 






CHAPTER TWO: IDENTIFICATION OF GENETIC ALTERATIONS IN 
ALT POSITIVE OSTEOSARCOMAS 
Adapted from Mason-Osann E et al. Oncotarget. 2018; 9(67) and Panier S, Maric 
M, Hewitt G, Mason-Osann E et al. Molecular Cell. 2019; 76 (1-17) 
Section 1: Abstract 
The Alternative Lengthening of Telomeres (ALT) pathway stimulates 
telomere elongation and prevents cellular senescence in approximately 60% of 
osteosarcoma.  While the precise mechanism underlying activation of the ALT 
pathway is unclear, mutations in the chromatin remodeling protein ATRX, histone 
chaperone DAXX, and the histone variant H3.3 correlate with ALT status.  ATRX 
and DAXX facilitate deposition of the histone variant H3.3 within heterochromatic 
regions suggestion that loss of ATRX, DAXX, and/or H3.3 lead to defects in the 
stability of telomeric heterochromatin.  Genetic mutations in ATRX, DAXX, and 
H3.3 have been detected in ALT positive cancers, however, a subset of ALT 
samples show loss of ATRX or DAXX protein expression or localization without 
evidence of genetic alterations, suggesting addition uncharacterized defects in 
ATRX/DAXX/H3.3 function. Here, using Next Generation Sequencing we 
identified a novel gene fusion event between DAXX and the kinesin motor 
protein, KIFC3, leading to the translation of a chimeric DAXX-KIFC3 fusion 
protein.  Moreover, we demonstrate that the fusion of KIFC3 to DAXX causes 
defects in DAXX function likely promoting ALT activity. These data highlight a 




osteosarcoma and provide rationale for thorough and comprehensive analyses of 
ATRX/DAXX/H3.3 proteins in ALT positive cancers. Furthermore, not all ALT 
tumors have dysfunction of the ATRX/DAXX/H3.3 chromatin-remodeling 
complex. As mechanisms of ALT are defined, more proteins involved in ALT 
regulation are identified, including SLX4IP and SMARCAL1. We characterized  
ATRX, DAXX, H3.3, SMARCAL1 and SLX4IP in a panel of osteosarcoma tumors 
and cell lines. In this work, we identified SLX4IP inactivation in a subset of ALT-
positive osteosarcomas, describing a novel gene deficiency associated with ALT 
activity.  
Section 2: Introduction 
Telomere elongation is a requisite for cellular immortality and a hallmark of 
cancer cells.  The majority of cancer cells rely on reactivation of the enzyme 
telomerase or activation of the ALT pathway to promote telomere elongation.  
The telomerase holoenzyme promotes telomere elongation by using the RNA 
component TERC as a template for reverse transcription at telomere ends.  ALT, 
however, promotes telomere elongation using homology-directed DNA damage 
repair via break induced replication (BIR) (73, 122, 202, 250).  Although it is 
unclear exactly how the recombinogenic state of ALT telomeres is established, 
uncapped or dysfunctional telomeres are believed to be an early event in the 
process(215, 241).  
ALT is a recombination-based mechanism where one telomere uses other 




telomere elongation. ALT was recently described to resemble BIR, a specific 
homology directed repair pathway utilized to repair one-sided DNA double-
stranded breaks that are often generated following replication fork collapse(122). 
Supporting this mechanism, ALT telomeres are characterized by high levels of 
replication stress and consequently, spontaneous DNA damage(64, 141, 212, 
241). Additionally, telomeres in ALT cells are found to be extremely 
heterogeneous in length, further supporting a role for recombination in ALT. ALT 
cells are also characterized by a number of unique cellular phenotypes including 
the formation of APBs(252). APB are nuclear domains that, in addition to the 
PML protein, contain telomeric DNA and a number of recombination and repair 
factors hypothesized to mediate ALT activity.  APB are unique to cells that rely 
on ALT for telomere elongation and have been used on clinical specimens to 
determine ALT status(199, 253). 
Genetically, ALT positive cancers frequently harbor inactivating mutations 
in the gene loci of a-thalassemia/mental retardation syndrome X-linked (ATRX), 
Death domain associated protein (DAXX), and H3 histone family member 3A 
(H3F3A/H3.3)(203, 215, 254). ATRX and DAXX form a complex that is 
responsible for the deposition of the histone variant H3.3 at heterochromatic 
regions to ensure transcriptional silencing and heterochromatin integrity(236, 
255–258).  Functional inactivation of ATRX, DAXX, or H3.3 lead to defects in 
heterochromatin formation at highly repetitive loci including pericentric, telomeric, 




defects in heterochromatin maintenance induce telomere dysfunction and 
contribute to the stimulation of ALT.  
Although genetic mutations in ATRX and DAXX are often demonstrated in 
ALT positive cancers, a fraction of cancers display significant defects in 
DAXX/ATRX protein expression and/or function that do not stem from genetic 
mutations(215). This observation has raised the possibility that other 
mechanisms likely contribute to functional inactivation of DAXX/ATRX proteins.  
Consistent with these studies, our data identify a novel structural rearrangement 
between the 3’UTR of DAXX and the kinesin family member KIFC3.  Moreover, 
we show that the resultant fusion protein compromises DAXX function and 
contributes to the ALT phenotype.  Our data provide additional support for 
functional inactivation of the ATRX/DAXX/H3.3 pathway in the absence of 
genetic mutations in the coding region of ATRX, DAXX, or H3.3 genes. 
Furthermore, while loss of ATRX, DAXX and H3.3 have long been 
associated with ALT telomere maintenance, not all ALT positive cancers show 
deficiency in one of these three genes.(199, 203, 215, 220, 259) As the 
mechanism of ALT is further investigated, more proteins have been identified as 
regulators or repressors of ALT activity, including SMARCAL1,(212, 227) a 
critical regulator replication of stress, and SLX4IP,(260) a protein regulating the 
activities of BLM and SLX4 at ALT telomeres. SMARCAL1 is lost in a subset of 
ALT positive cancers with wild-type ATRX(227), indicating that while ATRX, 




into the genetics of ALT positive cancers is needed to fully understand regulation 
of ALT activity. 
Section 3: Materials and Methods 
Cell Lines  
Cell lines were submitted for Short Tandem Repeat (STR) analysis and 
certificates of authentication can be provided upon request. G292, SJSA1 CAL78 
and HUO3N1 were cultured in RPMI 1640, 10% FBS, 1% Sodium Pyruvate and 
1% Penicillin/Streptomycin.  HOS were cultured in Eagle’s Minimum Essential 
Medium, 10% FBS, 1% Penicillin/Streptomycin.  HUO9 and NOS1 were cultured 
in RPMI 1640 5% FBS, 1% Sodium Pyruvate and 1% Penicillin/Streptomycin. NY 
and MG63 were cultured in DMEM/F12, 5% FBS, 1% Penicillin/Streptomycin. 
CAL72 were cultured in DMEM/F12, 10% FBS, 1% Penicillin/Streptomycin. 
U2OS were cultured in DMEM, 10% FBS, 1% Penicillin/Streptomycin.  SAOS2 
were cultured in RPMI 1640, 10% FBS, 1% Penicillin/Streptomycin. All cells were 
maintained at 37°C in a humidified incubator with 5% CO2 except for hFOB. 
hFOB were cultured in phenol red free DMEM/F12, with 10% FBS, 2.5 mM l-
glutamine, 0.3 mg/ml G418.  FOB were maintained at 34°C in a humidified 





RNA sequencing and alignment 
Total RNA was extracted from the three biological replicates of each cell 
line using Qiagen RNeasy Kit according to manufacturer’s instructions for RNA 
preparation. Samples were submitted to the BU Microarray and Sequencing Core 
for library preparation and ribosomal RNA reduction using Kapa RNA HyperPrep 
kit with Riboerase, and sequenced yielding 2x75bp paired-end read datasets. 
Read library quality was assessed using fastqc (FastQC 2016) and multiqc 
packages. Illumina adapters were removed and leading and trailing low-quality 
bases (below quality 30) were trimmed using Trimmomatic. Reads which were 
less than 36 bases long after these steps were dropped. The surviving reads 
were then mapped to the hg38 human reference genome using the STAR aligner 
with GENCODE v27 annotations. To more accurately quantify the reads mapped 
to novel splice junctions, 2-pass mapping mode was invoked in STAR. The RNA 
sequencing data discussed in this publication have been deposited in NCBI's 
Gene Expression Omnibus(261) and are accessible through GEO Series 
 accession number GSE118488 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118488). 
Fusion detection and visualization 
The fused-read junctions with statistics of chimeric alignments were 
filtered to eliminate chimeras with the mitochondrial genome, keeping only the 
canonical junctions with repeat length less than 5. Chimeric read alignment from 




supporting reads were filtered out. Genes at either end of the fusion were 
identified if any. To visualize the fusion between different chromosomes, a circos 
plot was made using the package OmicCircos. 
Antibodies, probes and plasmids 
The following antibodies and probes were used where indicated. ATRX 
(Cell Signaling, D1N2E), ATRX (Santa Cruz H-300), DAXX (Cell Signaling 
25C12), FLAG-M2 (Sigma F1804), GAPDH (Santa Cruz, 0411), Histone H3.3 
(Abcam, EPR17899), Histone H4 (Active Motif, 39269), PML (Santa Cruz H-238), 
PML (Santa Cruz PG-M3), α-Tubulin (Cell Signaling, 11H10), PCNA (Cell 
Signaling D3H8P), Purified Rabbit IgG (Bethyl Laboratories P120-101), 
SMARCAL1 (Santa Cruz, sc-376377), Alexa Fluor 488 conjugated Donkey Anti-
Rabbit IgG (Jackson ImmunoResearch), Cy3 conjugated Donkey anti-Rabbit 
(Jackson ImmunoResearch), Peroxidase conjugated Goat Anti-Mouse IgG 
(Jackson ImmunoResearch), Peroxidase conjugated Goat Anti-Rabbit IgG 
(Jackson ImmunoResearch).  PNA Telomere probe (TelC-Cy3, PNA Bio Inc.) 
Flag-DAXX/pRK5 was a gift from Xiaolu Yang (Addgene plasmid #27974). 
PCR Amplification & Gel Electrophoresis 
Cell pellets for each cell line were collected from actively growing cells. 
Genomic DNA (gDNA) and total cellular RNA were then extracted from the cell 
pellets using the QIAamp DNA Mini Kit (Qiagen #51304) and RNeasy Mini Kit 




experiments, 0.5 µg of total cellular RNA was converted to complementary DNA 
(cDNA) using the SuperScript IV Reverse Transcriptase protocol (Life 
Technologies #18090010) in a volume of 20 µl according to manufacturer’s 
instructions. gDNA or cDNA samples underwent three-step PCR amplification 
using Phusion High-Fidelity PCR Master Mix (Thermo Fisher #F-532S) according 
to manufacturer’s instructions. PCR reaction parameters were as follows: [1] 0:30 
at 98°C; [2] 0:10 at 98°C; [3] 0:30 at annealing temperature (60°C for GAPDH 
primers, 65°C for DAXX related primers); [4] 0:10 at 72°C; [5] Repeat steps 2-4 
for 29 cycles; [6] 10:00 at 72°C [7] Hold at 12°C.  PCR products were then 
resolved using agarose gel electrophoresis, stained using SYBR Gold (Thermo 
Fisher #S-11494), and visualized using a BioRad ChemiDoc XRS+ imaging 
system. 
Primers 
 DAXX Exon 7 Forward [5’: GTG GAA AGG CAA AGG TCA GT: 3’]; DAXX-
ZBTB22 Intergenic Reverse [5’: GAG GCA TTA TCG CTT GAG ACT G: 3’]; 
KIFC3 Exon 10 Reverse [5’: GAG CTC ATT GTG GCA CTT CTT A: 3’]; GAPDH 
Forward [5’: CAG AAC ATC ATC CCT GCC TCT AC: 3’]; GAPDH Reverse [5’: 
TTG AAG TCA GAG GAG ACC ACC TG: 3’]. ATRX Exon 1 Forward  [5’: AAT 
GGC TGA CGG AAA GAG AAA GAG: 3’]; ATRX Exon 1 Reverse [5’: CTC ATG 
GGC TCA GCG GTC ATG: 3’]; ATRX Exon 9 Forward [5’: GTG GTG TGC GGA 
AGG TGG AAA C: 3’]; ATRX Exon 9 Reverse  [5’: GGA GTT CAT GTT GGC 




ATG TCC: 3’]; ATRX Exon 35 Reverse [5’: CTT TGG GAC TGG CTC AGA TTA 
TAG: 3’] 
Sanger Sequencing 
Following visualization by gel electrophoresis, DNA was purified from 
individual bands using the GeneJET Gel Extraction Kit (Thermo Fisher #K-0691) 
according to manufacturer’s instructions. Samples were submitted for Sanger 
Sequencing to Genewiz, Inc. (Cambridge, MA) premixed in a volume of 15 µl 
containing 20 ng purified PCR product mixed with 25 pmoles primer templates. 
The previously described DAXX Exon 7 Forward, DAXX-ZBTB22 Intergenic 
Reverse, and KIFC3 Exon 9 Reverse primers sequences were used for 
sequencing. 
Spectral Karyotyping 
Spectral Karyotype analysis was performed at Roswell Park Cancer 
Institute Pathology Resource Network.  Cells were treated overnight with 0.03 
ug/ml of colcemid then harvested and fixed.  Metaphase spreads from fixed cells 
were then hybridized with SKY probe (Applied Spectral Imaging) for 36 hours at 
37 degrees Celsius.  Slides were then prepared for imaging using ASI’s CAD 
antibody kit and counterstained with DAPI.  Twenty metaphase spreads were 





Western blots were performed using standard protocols. Briefly, cells were 
collected by trypsinization and washed with ice-cold 1XPBS. Samples were then 
lysed in 2X Sample Buffer at 95 °C for 15 minutes before being sonicated in a 
water bath at 4 °C for 10 minutes (20-second pulse on/30-second pulse off at 
100% amplitude). Soluble protein lysates were then analyzed by western blot 
using standard SDS-PAGE techniques and transferred onto PVDF membranes. 
Membranes were blocked in TBST (1X TBS, 0.1% Tween-20) containing 5% milk 
and then incubated overnight at 4 °C with the appropriate primary antibodies.  
Following overnight incubation with primary antibodies, membranes were washed 
3 times in TBST, then incubated with peroxidase conjugated secondary 
antibodies and visualized using enhanced chemiluminescence reagents from 
BioRad and Thermo Fisher.  
siRNA Reverse Transfection 
For reverse transfection experiments, SJSA1 and G292 cells were initially 
seeded at a density of 150,000 cells/well and 220,000 cells/well respectively in a 
6-well plate and either mock transfected or transfected with siRNA SMARTpool 
(GE Dharmacon). Cells were transfected with 100 nM pooled siRNA using 
Lipofectamine RNAiMax (Thermo Fisher #18324012) diluted in Opti-MEM 
according to manufacturer’s instructions. 24 hours after initial transfection, the 
siRNA solution was removed and replaced with fresh media. Whole cell lysates 





siRNA Targeting Sequences: DAXX Pool LQ-004420-00-0002 à J-
004420-05 (CAG CCA AGC UCU AUG UCU A); J-004420-06 (GAG GUU AAC 
AGG CGC AUU G); J-004420-07 (GCS AAA CAA AGG ACG CAU A); J-004420-
08 (GGA GUU GGA UCU CUC AGA A); KIFC3 Pool LQ-008338-00-0002 à J-
008338-07 (GCU CUA UUC CCU CAA GUU U); J-008338-08 (CCA AUG CUG 
UGA CUU UCG A); J-008338-09 (GGU CAA GCC AGG AGC AUC U). 
Cellular Fractionation 
Cells were collected by trypsinization and lysed in CSK buffer (10mM 
Hepes pH 7.5, 10mM KCl, 2mM MgCl2, 300mM sucrose, 10% glycerol, 0.1% 
Triton-X-100) for 5 minutes on ice and then centrifuged for 5 minutes at 1,400 x g  
at 4°C.  The supernatant was collected and analyzed as the cytoplasmic fraction. 
The remaining cell pellet was again lysed in CSK buffer with 0.25% Triton-X-100 
for 5 minutes on ice, and centrifuged for 5 minutes at 1,400 x g at 4°C.   The 
supernatant was discarded and the cell pellet was washed in CSK buffer without 
Triton-X-100 and centrifuged for 5 minutes at 1,400 x g at 4°C.  The remaining 
cell pellet was then resuspended in NETN lysis buffer (150mM NaCl, 20mM 
TRIS-HCl pH 8.0, 0,5mM EDTA, 0.5% NP-40) for 30 minutes on ice with 
intermittent agitation. Samples were sonicated for a total of 10 minutes at 4°C 
(20-second pulse on/30-second pulse off at 100% amplitude) and centrifuged for 
10 minutes at 4 degrees at 17,000 x g.  The supernatant was collected and 





Cells were lysed in NETN buffer (150mM NaCl, 20mM TRIS-HCl pH 8.0, 
0,5mM EDTA, 0.5% NP-40) on ice for 30 minutes with intermittent agitation 
followed by sonication (QSonica Q800R3) for a total of 10 minutes at 4°C (20-
second pulse on/30-second pulse off at 100% amplitude). Samples were then 
centrifuged at 4°C for 10 minutes at 17,000 x g.  The supernatant was moved to 
a fresh Eppendorf tube and a portion of the sample was removed to use as the 
input.  3 ug of antibody (ATRX, Cell Signaling Technology D1N2E; PML, Santa 
Cruz Biotechnology PG-M3; IgG, Bethyl Laboratories) was added to the 
remainder of each sample and incubated overnight at 4°C with gentle shaking. 
The following day the samples were incubated with Protein A (ATRX) or Protein 
G (PML) coated magnetic beads (Thermo Fisher Scientific 10001D, 10003D) for 
30 minutes at room temperature. Beads were collected using magnetic 
separation, and subsequently washed in NETN buffer twice for 5 minutes each.  
Finally, beads were resuspended in 2X SDS sample buffer and boiled for 5 
minutes before analysis by SDS PAGE. 
Flag-DAXX overexpression 
G292 cells were forward transfected with Flag-DAXX/pRK5 using Fugene 
6 transfection reagent (Promega).  Cells were seeded onto coverslips overnight.  
The following day, 1.5 µl of Fugene 6 transfection reagent was mixed with Opti-
MEM, and 0.5 µg of Flag-DAXX/pRK5 in a total volume of 50µl.  After 15 




dish.  Transfection mixture was removed and media was replaced after 6-16 
hours.  For combined immunofluorescence and DNA FISH experiments, cells 
were reseeded after 48 hours and transfection was repeated after 72 hours.  
Overexpression was confirmed using western blot for DAXX (Cell Signaling 
25C12) 
Immunofluorescence 
For immunofluorescence, cells were rinsed with PBS and then pre-
extracted with 0.25% Triton-X in PBS for 1 minute at room temperature.  
Following pre-extraction, cells were rinsed with PBS, and then fixed in 4% 
paraformaldehyde for 10 minutes at room temperature.  Cells were rinsed with 
PBS and then permeabilized with 0.5% Triton-X in PBS for 15 minutes at room 
temperature.  Cells were incubated in blocking buffer (3% BSA, 0.05% Tween-20 
in PBS) for 10 minutes, and then incubated in primary antibody in blocking buffer 
overnight at 4°C (PML Santa Cruz PG-M3 1:300; DAXX Cell Signaling 25C12 
1:50).  The next day, following three 5 minute washed in PBS, cells were 
incubated in secondary antibody (anti-Rab Cy3 1:250; anti-Mouse AlexaFluor 
488 1:250) diluted in blocking buffer for 1 hour at room temperature. Finally, cells 
were washed three times for 5 minutes in PBS at room temperature, with DAPI 
added into the final wash.  The coverslips were mounted on glass microscope 
slides with Vectashield mounting medium and analyzed using a Zeiss LSM 710 




Combined Immunofluorescence and DNA fluorescence in situ hybridization 
Cells were rinsed with PBS and then treated with cytobuffer (100mM 
NaCl, 300mM Sucrose, 3 mM MgCl2, 10 mM PIPES pH 7, 0.1% Triton X-100) for 
7 minutes at 4°C.  Cells were then rinsed with PBS and fixed in 4% 
paraformaldehyde for 10 minutes at room temperature. Cells were permeabilized 
in 0.5% NP-40/PBS for 10 minutes and then blocked in PBG (0.5% BSA, 0.2% 
fish gelatin, PBS) for 1 hour at room temperature.   Cells were incubated in PML 
antibody (Santa Cruz H-238, 1:500) diluted in PGB overnight at 4°C.  Cells were 
washed three times with PBS for 5 minutes each and subsequently incubated 
with secondary antibody (Jackson ImmunoResearch Alexa Fluor488 conjugated 
donkey anti-Rabbit, 1:250) diluted in PBG for 45 minutes at room temperature.  
The cells were washed three times with PBS for 5 minute each, then fixed with 
4% paraformaldehyde for 10 minutes at room temperature.  Cells were digested 
with RNaseA 200µg/mL diluted in 2X SSC for 30 minutes at 37°C.  Cells were 
dehydrated in a series of ethanol washes, 70%, 85% then 100% for 2 minutes 
each at room temperature.  The coverslips were dried at 37°C for 20 minutes.  10 
nM telomere probe (PNA-Bio Tel-Cy3) was added to coverslips in hybridization 
buffer.  Slides were denatured at 85°C for 3 minutes, and then placed in a 
humidified chamber overnight at 37°C.  The following day, coverslips were 
washed in 2X SSC + formamide (mixed 1:1), three times for 5 minutes each at 
37°C, then washed in 2X SSC three times for 5 minutes each at 37°C, and finally 




dihydrochloride) for 20 minutes at room temperature.  The coverslips were 
mounted on glass microscope slides with Vectashield mounting medium and 
analyzed using a Zeiss LSM 710 confocal microscope.   
C-circle assay 
The C-circle assay was performed as previously described(213).  Briefly, 
genomic DNA was isolated using the Qiagen QiaAMP DNA Mini Kit according to 
the manufacturer’s instructions.  Purified DNA was digested with AluI and MboI 
restriction enzymes at 37°C overnight.  Digested DNA was purified using a 
Qiagen PCR clean-up kit according to the manufacturer’s instructions.  The DNA 
was quantified with a Nanodrop spectrophotometer and then diluted to 10 ng/µl.  
40 ng of gDNA was diluted in 25µl of 1X Φ29 buffer (NEB) containing BSA (NEB; 
0.08 mg/ml), 0.1% Tween, 0.25 mM each dATP, dGTP, dTTP and incubated in 
the presence or absence of 7.5 U Φ29 polymerase (NEB) at 30°C for 8 hours, 
following by 65°C for 20 minutes.   
Rolling circle amplification products were diluted to 10X SSC and run 
through a dot blot apparatus onto a Hybond N+ membrane using a BioRad dot 
blot vacuum manifold.  The membrane was crosslinked for 35 s (125J).  The 
membrane was incubated in Ultra-Hyb hybridization buffer (Ambion) for 1 hour at 
50°C.  Telomeric probe (CCCTAA)4 was labeled using the DIG oligonucleotide 3’- 
end labeling kit (2nd generation, Roche) according to manufacturer’s instructions.  
DIG labeled probe was added to the Ultra-Hyb hybridization buffer (1:1000) and 




twice with 2X SSC + 0.1% SDS at room temperature for 5 minutes each and 
twice with 0.5X SSC + 0.1% SDS at 50°C for 15 minutes each.  The membrane 
was developed using anti-DIG-AP (Roche), CDP-star (Roche), and the DIG 
Wash and Block Buffer set (Roche) following manufacturer’s instructions.  
Combined Immunofluorescence for PCNA and DNA fluorescence in situ 
hybridization 
For PCNA staining combined with telomere FISH, the same combined 
immunofluorescence and DNA FISH protocol used to stain PML and telomeres 
was followed with one exception. For staining with PCNA, cells were 
permeabilized in 100% cold methanol at -20°C for 10 minutes instead of 0.5% 
NP-40. Following permeabilization cells were blocked in PBG (0.5% BSA, 0.2% 
fish gelatin, PBS) for 1 hour at room temperature. 
 
Section 4: Results 
Identification of DAXX fusion transcript in ALT positive osteosarcoma 
There is a strong correlation between genetic mutations in 
ATRX/DAXX/H3.3 and cancers that rely on the ALT pathway for telomere 
maintenance.  However, a number of ALT positive tumors retain wild-type ATRX 
and DAXX gene loci yet demonstrate defects in ATRX and DAXX protein 
expression. These data suggest that functional inactivation of the 




asked whether we could identify defects in ATRX/DAXX/H3.3 using RNA 
sequencing on a panel of 13 osteosarcoma cell lines.  Of these cell lines, 8 
(U2OS, SAOS2, CAL72, CAL78, NY, NOS1, G292, and HUO9) have been 
previously characterized as ALT positive and 5 (HOS, MG63, SJSA1, hFOB1.19, 
and HUO3N1) have been characterized as ALT negative (Table 2.1, Fig 2.1A-B, 
and Fig 2.2A-D)(63, 215)  Although ALT status had been analyzed across the 
panel of cell lines CAL78, NY, and G292 were the only ALT positive cell lines that 
retained ATRX/DAXX/H3.3 protein expression(63, 215) (Table 2.1).  Following 
RNA sequencing and western blot analysis we found that CAL78 and NY 
demonstrated loss of expression of the SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily a like 1 (SMARCAL1) gene and a 
corresponding loss of full length SMARCAL1 protein expression (Table 2.1 and 
Fig 2.2D).  Likewise, a recent publication reported SMARCAL1 mutations in ALT 
positive glioblastomas as well as in the CAL78 cell line (227). SMARCAL1 is an 
annealing helicase that functions to remodel chromatin surrounding sites of 
stalled replication forks and has been demonstrated to function to resolve 
replication stress at telomeric DNA suggesting that defects in SMARCAL1 





1See Figure 2.2A-B 
2See Figure 2.2C 
3As reported in Lovejoy et al PLoS Genetics (2014) 
4As reported in Heaphy et al Science (2011) 
5As reported in Mason-Osann et al Oncotarget (2018) 
6See Figure 2.2D 
7As reported in Diplas et al Nature Communications (2018) 
8See Figure 2.1 





Table 2.1 – Genetic characterization of osteosarcoma cell lines and patient derived 
xenograft tumors.  
* Adapted from Mason-Osann E et al. Oncotarget. 2018; 9(67)  
 
ATRX, DAXX, H3.3 and SMARCAL1 status are indicated based on this and previously published 




Cell line ATRX DAXX H3.3 SMARCAL1 SLX4IP ALT STATUS 
MG63 ✓	 ✓	 ✓	 ✓	 ✓	 Non-ALT 
SJSA1 ✓	 ✓	 ✓	 ✓	 ✓	 Non-ALT 
hFOB1.19 ✓	 ✓	 ✓	 ✓	 ✓	 Non-ALT8 
HOS ✓	 ✓	 ✓	 ✓	 ✓	 Non-ALT 
HUO3N1 ✓	 ✓	 ✓	 ✓	 ✓	 Non-ALT8 
HUO9 Abnormal expression No Full Length protein1 ✓	 ✓	 ✓	 ✓	 ALT 
NOS1 Exon Deletion
2 
No Full Length protein ✓	 ✓	 ✓	 ✓	 ALT 
NY ✓	 ✓	 ✓	 No Full Length protein6 ✓	 ALT 
CAL72 Exon Deletion
2 
No Full Length protein ✓	 ✓	 ✓	 ✓	 ALT 
CAL78 ✓	 ✓	 ✓	 Deletion
6,7 
No Full Length protein1 ✓	 ALT 
SAOS2 Abnormal expression No Full Length protein1,3 ✓	 ✓	 ✓	 ✓	 ALT 
U2OS Exon Deletion
2,3,4 
No Full Length protein1 ✓	 ✓	 ✓	 ✓	 ALT 
G292 ✓	 T(6;16)5  ✓	 ✓	 ✓	 ALT 
Tumors9 ATRX DAXX H3.3 SMARCAL1 SLX4IP ALT STATUS 
OS1 ✓	 ✓	 ✓	 ✓	 ✓	 ALT 
OS2 ✓	 No protein ✓	 ✓	 ✓	 ALT 
OS9 ✓	 ✓	 ✓	 ✓	 No protein ALT 
OS17 ✓	 ✓	 ✓	 ✓	 No protein ALT 
OS29 ✓	 ✓	 ✓	 ✓	 No protein ALT 
OS31 No protein ✓	 ✓	 ✓	 ✓	 ALT 







Figure 2.1 – ALT status determined by C-circles and PCNA colocalization. 
* Adapted from Mason-Osann E et al. Oncotarget. 2018; 9(67) 
 
A) Dot blot results from C-circle assay performed using 40ng genomic DNA isolated from 
SaOS2 (positive control), SJSA1 (negative control), HuO3N1 or hFOB1.19. C-circle 
assay was performed with or without Phi29 polymerase. 
B) Quantification of focal PCNA colocalization with telomeric DNA is SaOS2, SJSA1, 
HuO3N1, hFOB1.19 cells.  Cells were staining for PCNA using immunofluorescence and 
telomeres using fluorescence in situ hybridization with a telomere specific probe. n=3 


















Supplementary Figure 2: (A) Dot blot result from C-circle assay performed using 40 ng genomic DNA isolated from SAOS2 (positive 
control), SJSA1 (negative control), HUO3N1 or hFOB1.19 cells. C-circle assay was performed with or without Phi29 polymerase. (B) 
Quantification of focal PCNA colocalization with telomeric DNA in SaOS2, SJSA1, HUO3N1 or hFOB1.19 cells. Cells were stained for 
PCNA using immunofluorescence and telomeres using fluorescence in situ hybridization with a telomere specific probe. n = 3 independent 
experiments with ≥ 100 cells counted per experiment.
Supplementary Figure 3: (A) Representative image from the Integrated Genomics Viewer (IGV) displaying RNA sequencing reads 
aligned to the ATRX gene (hg38) from SJSA1, HUO9 and SAOS2 cells. Red connecting arcs represent predicted splice junctions between 
exons in the RNA from each individual cell line. Blue vertical bars in the ATRX reference gene represent the exons. (B) Western blot of a 
panel of cell lines for ATRX. ATRX runs above 250 kDa, the remaining bands represent alternative isoforms or degradation products. (C) 
PCR amplification products of exon 1, exon 9 or exon 35 of ATRX from genomic DNA isolated from SJSA1, U2OS, SAOS2, HUO9, NOS1 






Figure 2.2 – Characterization of ATRX and SMARCAL1 in osteosarcoma cell lines. 
* Adapted from Mason-Osann E et al. Oncotarget. 2018; 9(67) 
 
A) Representative image from the Integrated Genomics Viewer (IGV) displaying RNA 
sequencing reads aligned to the ATRX gene (hg38) from SJSA1, HuO9, SaOS2 cells. 
Red connecting arcs represent predicted splice junctions between exons in the RNA from 
each individual cell line. Blue vertical bars in the ATRX reference gene represent the 
exons. 
B) Western blot of a panel of cell lines for ATRX. ATRX runs above 250 kDa, the remaining 
bands represent alternative isoforms or degradation products. 
C) PCR amplification products of exon 1, exon 9 or exon 35 of ATRX from genomic DNA 
isolated from SJSA1, U2OS, SaOS2, HuO9, NOS1 or Cal72. 




Supplementary Figure 2: (A) Dot blot result from C-circle assay performed using 40 ng genomic DNA isolated from SAOS2 (positive 
control), SJSA1 (negative control), HUO3N1 or hFOB1.19 cells. C-circle assay was performed with or without Phi29 polymerase. (B) 
Quantification of focal PCNA colocalization with telomeric DNA in SaOS2, SJSA1, HUO3N1 or hFOB1.19 cells. Cells were stained for 
PCNA using immunofluorescence and telomeres using fluorescence in situ hybridization with a telomere specific probe. n = 3 independent 
experiments with ≥ 100 cells counted per experiment.
Supplementary Figure 3: (A) Representative image from the Integrated Genomics Viewer (IGV) displaying RNA sequencing reads 
aligned to the ATRX gene (hg38) from SJSA1, HUO9 and SAOS2 cells. Red connecting arcs represent predicted splice junctions between 
exons in the RNA from each individual cell line. Blue vertical bars in the ATRX reference gene represent the exons. (B) Western blot of a 
panel of cell lines for ATRX. ATRX runs above 250 kDa, the remaining bands represent alternative isoforms or degradation products. (C) 
PCR amplification products of exon 1, exon 9 or exon 35 of ATRX from genomic DNA isolated from SJSA1, U2OS, SAOS2, HUO9, NOS1 




Out of the 8 ALT positive cell lines analyzed, G292 was the only remaining 
cell line without a characterized defect in the genes currently associated with 
ALT.  Therefore, in addition to analysis of simple gene expression, we also 
analyzed putative gene fusion events across our 13 cell lines and identified 
chimeric reads in the ALT positive G292 cell line data that aligned to both the 
DAXX and the kinesin family member, KIFC3 gene loci (Fig 2.3A and Fig 2.4).  
These chimeric reads suggested a transcriptional fusion between DAXX and the 
kinesin family member, KIFC3. The DAXX-KIFC3 chimeric reads suggested two 
transcript fusion events, a less abundant event located between position 
c.33318688 on chromosome 6 and c.57766986 on chromosome 16 and a more 
highly expressed event between c.33318996 on chromosome 6 and c.57766986 
on chromosome 16 (using the hg38 genomic assembly).  To further validate the 
transcript fusion between DAXX and KIFC3 in this sample we isolated RNA from 
both G292 cells and a telomerase positive osteosarcoma cell line, SJSA1.  
Following RT-PCR with primer pairs that flanked the predicted fusion sites we 
confirmed the presence of a single PCR product in the G292 cell line that was 
not amplified in the SJSA1 control suggesting that a single mature transcript had 
been generated (Fig 2.3B).  We then purified the PCR product and analyzed the 
DNA by Sanger sequencing (Fig 2.3C).  The sequencing reaction confirmed a 










Figure 2.3 – Identification of a DAXX-KIFC3 fusion transcript in an ALT positive 
osteosarcoma. 
* Adapted from Mason-Osann E et al. Oncotarget. 2018; 9(67) 
 
A) Circos plot generated using the OmicCircos package following RNA sequencing of the 
G292 cell line. Lines represent the predicted interchromosomal fusion transcripts.    
B) RT-PCR amplification products from SJSA1 and G292 RNA using primers that either 
flank the predicted transcriptional fusion site or amplify GAPDH as a control.   
C) Representative chromatogram of the Sanger sequencing results from the RT-PCR 
product generated from G292 RNA.  Sequence shown highlights the region where the 
fusion event between DAXX and KIFC3 occurs.   
D) Schematic of the fusion transcript that contains exons 1-7 of DAXX and exons 10-20 of 
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Figure 2.4 – Representative image from IGV genome browser displaying RNA sequencing 
reads aligned to DAXX exon 7 from G292. 
* Adapted from Mason-Osann E et al. Oncotarget. 2018; 9(67) 
 
White bars represent the portion of the sequencing reads that align to DAXX using the reference 
genome (hb38). Colored bars represent the portion of the read that does not align to DAXX using 
the reference genome, but instead aligns to the KIFC3 gene (not pictured) 
  
Supplementary Figure 4: Representative image from IGV genome browser displaying RNA sequencing reads aligned 
to DAXX exon 7 from G292 cells. White bars represent the portion of the sequencing reads that align to DAXX using the reference 
genome (hg38). Colored bars represent the portion of the read that does not align to DAXX using the reference genome, but instead aligns 
to the KIFC3 gene (not pictured).
Supplementary Figure 5: Representative G292 metaphase spreads analyzed by spectral karyotyping. The t(6;16) 




Characterizing the structural rearrangement in the DAXX gene locus 
To further define the genomic rearrangement that gave rise to the DAXX-
KIFC3 fusion transcript we analyzed the genomic DNA isolated from G292 and 
SJSA1 cells.  As with our previous analysis on the isolated RNA, we isolated 
genomic DNA from either SJSA1 or G292 and performed PCR analysis with 
primer pairs that flanked the predicted fusion sites.  While we were unable to 
detect a PCR product in the genomic DNA from SJSA1 cells, we were able to 
detect a single band in the genomic DNA from G292 cells (Fig 2.5A).  Following 
gel extraction and Sanger sequencing of this PCR product we were able to 
confirm a genetic fusion between DAXX and KIFC3 (Fig 2.5B).  Interestingly, our 
data demonstrate that the fusion of the two genes lies between the 3’UTR of 
DAXX and intron 9 of KIFC3 (Fig 2.5C-D).  Thus, while the coding region of exon 
8 of the DAXX gene is intact following translocation, this exon is spliced from the 
mRNA transcript.  Therefore, in addition to the translocation at the DNA level, 
there are also defects in DAXX splicing that contribute to the expression of the 
fused transcript.      
Given the importance of DAXX function in heterochromatin integrity, we 
were also interested in determining whether the G292 cells also maintained a 
copy of the wild-type DAXX allele.  The genomic data demonstrate that the 
3’UTR of DAXX is fused to KIFC3 leading to either displacement, or loss, of the 





Figure 2.5 – Structural characterization of the DAXX gene locus. 
* Adapted from Mason-Osann E et al. Oncotarget. 2018; 9(67) 
 
A) PCR amplification of the wild type DAXX gene locus or the DAXX-KIFC3 fusion using 
genomic DNA isolated from SJSA1 or G292 cells.  GAPDH was amplified as a control. 
Used forward primer for DAXX exon 7 and reverse primer for either the intergenic region 
between DAXX and ZBTB22 (WT), or KIFC3 exon 10 reverse (DAXX-KIFC3 fusion) 
B) Representative chromatogram from Sanger sequencing of the DAXX-KIFC3 gene fusion 
PCR product amplified from G292 cells.  Sequence shown highlights the region where 
the fusion event occurs at the genomic DNA level now defined as t(6:16).   
C) Schematic of the t(6;16) fusion in genomic DNA in G292. The 3’UTR of DAXX is fused to 
intron 9 of KIFC3.  Wild type DAXX primers are shown in green, t(6;16) primers are 
shown in orange.   
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Figure 2.6 – Representative G292 metaphase spreads analyzed by spectral karyotyping. 
* Adapted from Mason-Osann E et al. Oncotarget. 2018; 9(67) 
 
The t(6;16) translocation, changes in ploidy and chromoanagenesis are evident in metaphases 
shown in both A and B. 
  
Supplementary Figure 4: Representative image from IGV genome browser displaying RNA sequencing reads aligned 
to DAXX exon 7 from G292 cells. White bars represent the portion of the sequencing reads that align to DAXX using the reference 
genome (hg38). Colored bars represent the portion of the read that does not align to DAXX using the reference genome, but instead aligns 
to the KIFC3 gene (not pictured).
Supplementary Figure 5: Representative G292 metaphase spreads analyzed by spectral karyotyping. The t(6;16) 




the wild-type (WT) allele of DAXX were present in the sample, we should be able 
to detect WT DAXX using primers that recognized the genomic DNA downstream 
of the DAXX 3’ UTR.  Therefore, we generated primers that encompassed the 
genomic DNA on chromosome 6 between exon 7 of DAXX and the intergenic 
region between DAXX and the 5’ UTR of the neighboring gene, ZBTB22 (Fig 
2.5C).  While we were able to amplify a PCR product from the genomic DNA 
isolated from SJSA1 cells, we were unable to generate a PCR product from the 
genomic DNA of the G292 cells (Fig 2.5A).  Following purification of the PCR 
product and Sanger sequencing we were able to confirm that the product 
generated from the genomic DNA of SJSA1 contained the predicted region on 
chromosome 6 between DAXX and the ZBTB22 gene.  Given that we were 
unable to detect this DAXX-containing product in the G292 cell line these data 
suggest that the DAXX-KIFC3 fusion mutation is accompanied by loss of 
heterozygosity for the remaining WT DAXX allele. 
To further define the DAXX-KIFC3 translocation event we performed 
spectral karyotype (SKY) analysis on metaphases spreads prepared from G292 
(Fig 2.5D, Fig 2.6). This analysis revealed an abnormal human female karyotype 
with a modal chromosome number of 60.  Consistent with osteosarcoma tumors, 
the G292 sample demonstrated whole chromosome gains and losses and a large 
number of structural rearrangements including whole chromosome arm deletions 
and translocations (Fig 2.6).  Of the twenty metaphase spreads analyzed 100% 




with no evidence of unperturbed chromosomes 6 or 16 in this cell line.  The 
translocation, now referred to as t(6:16)(6p21:16q21), was not found in 
metaphase spreads isolated from normal peripheral blood monocytes grown in 
culture (Fig 2.7).  These analyses confirm that fragments of chromosome 16 
containing the KIFC3 gene aberrantly fused to the DAXX gene on chromosome 
6.  Furthermore, this translocation was found in multiple copies in each cell 
suggesting genome reduplication following the translocation event that was then 
selected for during the evolution of the tumor. In addition to this translocation, our 
data highlight the presence of complex genomic rearrangements of chromosome 
8, 6, and 15 that were also present in 100% of the metaphase spreads analyzed 
indicative of chromoanagenesis (Fig 2.5D and Fig 2.6)(262).  
Characterizing the function of the DAXX-KIFC3 chimeric protein 
Given that the translocation was expressed and the mature transcript 
preserved the integrity of the fused exons, we asked whether the transcript was 
also translated into a stable protein product.  While SJSA1 cells demonstrated 
DAXX protein product at the predicted size by western blot, this WT DAXX 
product was absent in G292 cells.  Instead, G292 cells demonstrated a much 
higher migrating DAXX species, approximately 40kDa larger than WT DAXX (Fig 
2.8A).  To confirm that this higher migrating DAXX species represented a DAXX-
KIFC3 fusion protein, we transfected both SJSA1 and G292 cells with siRNA 








Figure 2.7 –  Representative metaphase spread prepared from normal peripheral blood 
monocytes. 
* Adapted from Mason-Osann E et al. Oncotarget. 2018; 9(67) 
 
Metaphases were stained by FISH for chromosome 6 (green) and chromosome 16 (red). Normal 
peripheral blood monocytes contain two copies of chromosome6 and 2 copies of chromosome 16 
as expected. Analysis was performed by Brigham and Women’s Hospital Department of 
Pathology CytoGenomics Core. 
  
Supplementary Figure 6: Representative metaphase spread prepared from peripheral blood monocytes following 
FISH with whole chromosome paint for chromosome 6 (green) and chromosome 16 (red). Normal peripheral blood 
monocytes contain two copies of chromosome 6 and 2 copies of chromosome 16 as expected. Analysis was performed by Brigham and 




maintained in the fused transcript.  The siRNAs targeting either DAXX or KIFC3, 
both led to an almost complete loss of the higher migrating DAXX species 
confirming that this protein product is in fact a DAXX-KIFC3 chimeric protein (Fig 
2.8B).  We also observed several weak bands that migrated at a lower molecular 
weight in the G292 sample.  Notably these bands were undetectable after 
treatment with not just the DAXX siRNA, but also the KIFC3 siRNA in whole-cell 
extracts confirming that these smaller species were likely degradation products 
or alternatively processed transcripts of the fusion protein and unlikely to be other 
isoforms of the wild-type DAXX protein. 
DAXX has been described to localize within both the cytoplasmic and 
nuclear compartments of the cell(263–265).  However, as a member of the 
kinesin super family, KIFC3 functions as a molecular motor that regulates 
intracellular transport in the cytoplasm(266, 267).  Structurally, KIFC2 and KIFC3 
are the only two known kinesin genes that have the motor domain located in the 
carboxy terminus and maintain minus end-directed motility along microtubule 
fibers(268). Following the fusion with DAXX, the KIFC3 gene retained the 
microtubule-binding domain. The cytoplasmic localization of KIFC3 and 
association with microtubules, coupled with the nuclear localization of DAXX led 
us to speculate that KIFC3 may sequester DAXX in the cytoplasm inhibiting 
nuclear DAXX function.  To further characterize the effects of the DAXX-KIFC3 






Figure 2.8 –  The DAXX-KIFC3 fusion leads to expression of a chimeric protein. 
* Adapted from Mason-Osann E et al. Oncotarget. 2018; 9(67) 
 
A) Western blot of SJSA1 and G292 cells for DAXX, ATRX, H3.3 or a-tubulin.  Chimeric 
DAXX-KIFC3 protein runs at a higher molecular weight in G292 cells compared to wild 
type DAXX in SJSA1 cells.   
B) Western blot for DAXX in SJSA1 and G292 cells following 48 hour reverse transfection 
with 100nM siRNA targeting either DAXX (left panel) or KIFC3 (right panel). a-tubulin was 
used as a loading control.   
C) Western blot for DAXX, GAPDH and Histone H4 following cellular fractionation. Nuclear 
fractions (NUC), cytoplasmic fractions (CYTO) or whole cell extracts (WCE) of SJSA1 
and G292.  GAPDH and Histone H4 were used to demonstrate successful separation of 
cytoplasmic and nuclear fractions.   
D) Immunoprecipitation of ATRX followed by ATRX, DAXX, and H3.3 detection by Western 
blot in SJSA1 and G292. 
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and G292 cells.  Following cellular fractionation, we detected the majority of the 
DAXX protein localized within the nuclear compartment in both SJSA1 and G292 
cells (Fig 2.8C) suggesting that the fusion of DAXX to KIFC3 does not affect 
DAXX localization within the nucleus.   
Defects in DAXX-KIFC3 function 
Our Sanger sequencing results from the RNA fusion transcript 
demonstrated that the N-terminal portion of DAXX within the chimeric protein 
retained both the ATRX and H3.3 binding domains.  Given that both ATRX and 
H3.3 proteins were expressed in G292 cells (Fig 2.8A) we asked whether the 
ATRX, DAXX, and H3.3 complex was preserved in the presence of the DAXX-
KIFC3 fusion protein.  Although we would have preferred to immunoprecipitate 
DAXX directly, several attempts using multiple different DAXX antibodies were 
unsuccessful. Therefore, we immunoprecipitated ATRX from either SJSA1 or 
G292 cells and confirmed that the interaction between ATRX, DAXX, and H3.3 
was retained in G292 cells (Fig 2.8D).   
DAXX localization and function have also been linked to sumoylation and 
sumo-mediated interactions(263, 264, 269–271).  While the N-terminus of DAXX 
is retained after fusion with KIFC3, the extreme C-terminus of DAXX including 
exon 8, is completely lost. Exon 8 is composed of amino acid residues 733-740 
and constitutes a sumo interacting motif (SIM). The DAXX SIM is required not 
only for recognition of other sumoylated proteins, but also essential for DAXX 




interaction with PML and regulate the association of DAXX to PML nuclear 
bodies(270, 271).  Moreover, the C-terminus of DAXX has been demonstrated to 
be essential for the recruitment of DAXX to telomeres(272).  Thus, the DAXX-
KIFC3 chimeric protein would not retain wild-type DAXX function either within 
PML nuclear bodies or at telomeric DNA, loss of both of these activities have 
been hypothesized to promote ALT activity.  To determine whether DAXX-KIFC3 
fusion protein localized to PML we used G292 cells alone, or G292 cells that 
overexpressed the Flag-tagged DAXX and analyzed the localization of DAXX to 
PML nuclear bodies by immunofluorescence (Fig 2.9A). As expected, the 
exogenously expressed DAXX protein forms distinct nuclear foci that colocalize 
to PML nuclear bodies.  However, the endogenous DAXX-KIFC3 fusion protein 
did not localize to PML confirming defects in DAXX protein function (Fig 2.9B).  
Given that the DAXX-KIFC3 fusion protein fails to fully establish wild-type 
(WT) DAXX function we reasoned that this deficit in DAXX function was 
contributing to the ALT phenotype.  To confirm this, we asked whether 
expression of exogenous WT DAXX and consequently, partial restoration of 
DAXX function could repress ALT activity.  Previous studies have demonstrated 
that expression of ATRX in an ATRX deficient ALT positive cancer cell can 
repress ALT phenotypes including the formation of APB(219). Therefore, we 
analyzed APB formation by immunofluorescence in control G292 cells or cells 
that had been transfected with WT DAXX.  While the control cells consistently 




Figure 2.9 – Expression of WT DAXX represses APB formation. 
* Adapted from Mason-Osann E et al. Oncotarget. 2018; 9(67) 
 
A) Western blot of G292 cells either mock transfected or transfected with wild-type Flag-
DAXX detecting DAXX or a-tubulin.  Both chimeric DAXX and Flag-DAXX are detected in 
the transfected cells, with chimeric DAXX running at a higher molecular weight than wild-
type Flag-DAXX.  
B) Representative images from immunofluorescence analysis of G292 cells mock 
transfected or G292 cells transfected with Flag-DAXX for 2 days. Cells were stained for 
DAXX, PML and DAPI. Scale bar is 10µm.   
C) Representative images of combined immunofluorescence-FISH analysis of APBs in mock 
transfected G292 cells or G292 cells transfected with Flag-DAXX for 2 or 6 days.  Cells 
were stained by immunofluorescence for PML and FLAG, and by FISH for telomeres. 
Arrow indicates APB in a positive cell. Scale bar is 10µm.    
D) Quantification of APB data shown in C), counting a cell positive for APB if it has >1 large 
or 3 small telomere colocalization events and counting a cell positive for Flag-DAXX 
transfection if it has ≥3 Flag foci.  P-values denoted comparing mock and Flag-DAXX 
transfected cells at each time point using two-way ANOVA followed by Bonferroni test for 




















































demonstrated a significant and progressive decrease in APB at both 2 and 6 
days following transfection (Fig 2.9C-D). Taken together, re-expression of WT 
DAXX in G292 cells partially restored DAXX function and repressed ALT 
phenotypes. 
SLX4IP is lost in a subset of ALT-positive osteosarcomas  
To date ALT is known to be associated with genetic defects in ATRX, 
DAXX, and SMARCAL1 (199, 203, 227, 273). However, there are a number of 
ALT positive cell lines and tumors in which the ATRX, DAXX, and SMARCAL1 
genes are unperturbed (215, 274). (Table 2.1) In light of recent findings linking 
SLX4IP to ALT telomere maintenance, we asked whether SLX4IP is inactivated 
in a panel of osteosarcoma tumors, which frequently employ the ALT pathway.  
To do this, we conducted RNA sequencing analysis of the 7 osteosarcoma 
tumors and 13 osteosarcoma cell lines. To proceed we needed to first identify the 
telomere maintenance mechanism utilized in each of the cell lines or tumors. We 
analysed the expression of the telomerase gene hTERT to determine if any of 
these tumors and cell lines could have retained telomerase activity.  As expected 
we were able to detect hTERT expression in the cell lines known to retain 
telomerase activity but were unable to detect hTERT expression in the cell lines 
known to retain ALT activity. Interestingly, none of the 7 osteosarcoma tumors 
demonstrated hTERT expression suggesting that this subset of osteosarcoma 
tumors lack telomerase activity (Fig 2.10A).  As demonstrated by two of the cell 




and ALT activity, thus the absence of hTERT expression is not necessarily 
indicative of ALT activity. Therefore, we analysed our panel of tumor lines for the 
formation of extra-chromosomal telomeric repeat DNA, in the form of C-circles, a 
hallmark of ALT activity. Considering that none of our tumors retained telomerase 
activity, we also generated xenografted tumors using the telomerase positive cell 
line SJSA1 to serve as a negative control for the C-circle assays.  Following DNA 
extraction and rolling circle amplification, all 7 tumors demonstrated C-circle 
abundance greater than the C-circle abundance generated in the SJSA1 control 
tumors confirming that all 7 tumors possess ALT activity (Fig 2.10B).   
 We then asked whether any of these tumors had deficiencies in any of the 
genes associated with ALT activity including ATRX, DAXX, H3.3, and 
SMARCAL1.  Of the 7 tumors, only 2 tumors (OS31 and OS33) had structural 
variations in ATRX by RNA sequencing while the 5 remaining tumors (OS1, OS2, 
OS9, OS17, OS29) retained RNA expression of DAXX, SMARCAL1, and H3.3. 
(Fig 2.10F) Strikingly, we found that of these 5 remaining tumors 3 tumors, OS9, 
OS17, and OS29 demonstrated complete loss of SLX4IP expression by RNA 
sequencing analysis (Fig 2.10C). To confirm this result, we analysed the 7 
osteosarcoma tumor samples for ATRX, DAXX, SMARCAL1, H3.3, and SLX4IP 
protein expression by western blot (Fig 2.10D-E).  As predicted by the RNA 
sequencing analysis, OS31 and OS33 demonstrate a loss of ATRX protein 





 Figure 2.10 –  SLX4IP is lost in a subset of ALT positive osteosarcomas 
*Adapted from Panier S, Maric M, Hewitt G, Mason-Osann E et al. Molecular Cell. 2019; 76 (1-
17) 
A) Relative expression of hTERT from RNA sequencing preformed on a panel of 
osteosarcoma cell lines and patient-derived osteosarcoma xenografts. RNA sequencing 
was performed in triplicate, and each dot represents a separate experiment. 
B) Quantification of C-circle abundance in the osteosarcoma PDX samples. DNA was 
extracted from three separate tissue sections taken from each tumor. DNA extracted from 
HUO9 cells was used as a positive control, and DNA extracted from SJSA1 xenografts 
was used as a negative control. Data are represented as mean ± SD; n = 3. Dotted line 
represents 5-fold change in C-circle abundance. 
C) Relative expression of SLX4IP from RNA sequencing preformed on a panel of 
osteosarcoma cell lines and patient-derived osteosarcoma xenografts. RNA sequencing 
was performed in triplicate, and each dot represents a separate experiment. 
D) Whole-cell extracts of the indicated cell lines were analyzed by SLX4IP immunoblotting. 
α-Tubulin was used as loading control. 
E) PDX tumor samples were analyzed by SLX4IP, ATRX, SMARCAL1, DAXX and H3.3 
immunoblotting. α-Tubulin was used as loading control. Arrow indicates SLX4IP band.  




OS9, OS17, and OS29 demonstrated loss of SLX4IP protein expression whilst 
retaining ATRX, DAXX, SMARCAL1 and H3.3 protein expression.   
In addition to the 7 tumors, we also analysed all 13 cell lines for ATRX, 
DAXX, SMARCAL1, H3.3, and SLX4IP protein expression by immunoblotting 
(274) (Fig 2.10D-E).  Consistent with the analysis in our tumor samples, SLX4IP 
deficiencies in our cell lines are mutually exclusive with ATRX, DAXX, 
SMARCAL1, and H3.3 raising the possibility that SLX4IP may represent another 
gene deficiency associated with ALT activity.  Notably, we identified one cell line, 
HUO3N1, that does not maintain telomerase nor ALT activity, yet is deficient for 
SLX4IP (Fig 2.10D).  Collectively our data suggest that loss of SLX4IP likely 
contributes to the maintenance of ALT activity, but similar to ATRX, DAXX, and 
SMARCAL1 its loss is not sufficient to induce ALT. (Data summarized in Table 
2.1) 
 
Section 5: Discussion 
Cancer cells can overcome telomere attrition and promote cellular 
immortality by exploiting mechanisms of telomere elongation.  Reactivation of the 
enzyme telomerase, or activation of the ALT pathway, account for cellular 
immortalization in the majority of human cancers.  Although the ALT mechanism 
is active in roughly 5% of all human cancers, this incidence skyrockets to 
approximately 60% in some of the most aggressive forms of human cancer, 




development of novel therapeutic strategies in the treatment of these highly 
aggressive cancers.  However, the mechanistic basis of ALT activation has not 
been fully elucidated.  The identification of genetic mutations in ATRX, DAXX, 
H3.3, and more recently SMARCAL1 in ALT positive cancers has been 
instrumental in further defining the molecular basis of ALT.   However, defects in 
ATRX, DAXX, and H3.3 protein function have also been described in the 
absence of a clear mutation in the coding sequence suggesting alternative 
mechanisms to functionally inactivate the ATRX/DAXX/H3.3 axis.  Our data 
characterize a translocation between the untranslated region of the DAXX gene 
and a central intron of the kinesin family member KIFC3 that leads to the 
expression of a DAXX-KIFC3 fusion protein.  The fusion causes defects in DAXX 
protein function and contributes to activation of the ALT pathway. Interestingly, 
the cytogenic band on chromosome 6 containing the DAXX gene, 6p21, and the 
cytogenic band on chromosome 16 containing KIFC3, 16q21 have both been 
identified as common fragile sites within the genome suggesting that these 
regions are unstable and may be susceptible to DNA double-strand breaks and 
ultimately, genomic rearrangements(275–277). To our knowledge this is the first 
report to characterize a defect in DAXX protein in osteosarcoma highlighting a 
novel mechanism for functional inactivation of DAXX in ALT. 
Osteosarcoma is rare, with approximately 800 cases reported in the 
United States each year(278).  Thus, the availability of tumor tissue and or large 




of the t(6:16) translocation in osteosarcoma we looked to analyze existing 
publicly available datasets for osteosarcoma tumors. The chimeric reads 
identified in our RNA sequencing analysis would not have been detected by 
whole-exome sequencing as the coding region of DAXX is wild-type. Therefore, 
our search was limited to studies that had generated whole genome sequencing 
or RNA sequencing data.  To our knowledge, the Osteosarcoma Genomics study 
(dbGaP Study Accession pht004384.v1.p1) is one of the largest publicly 
available datasets for osteosarcoma and this study contains RNA sequencing 
data for 35 tumors (279) highlighting the limited availability of next generation 
sequencing in pediatric osteosarcoma.  While the DAXX-KIFC3 fusion in G292 
was annotated in the CCLE we were unable to detect the t(6:16) translocation in 
the 35 tumor samples from the Osteosarcoma Genomic Study and this 
translocation was not annotated in the cBioPortal database.  In total, 451 
mutations have been described for DAXX in cBioPortal across all of the available 
tumor types.  Notably, this database does not contain data specifically for 
osteosarcoma tumors.  Of the DAXX mutations cataloged, approximately 87.1% 
are substitution mutations, 12.1% are insertion/deletion mutations, and 0.66% 
are fusion mutations.  Of the substitution mutations, several lie in the C-terminus 
of DAXX. One in particular, 733* leads to the incorporation of a premature stop 
codon and a truncated DAXX protein that lacks exon 8 highlighting the 
significance of exon 8 in DAXX function.  The three fusion events that have been 




and lead to the fusion of DAXX with other genes located in the 6p21 cytogenic 
band including UHRF1BP1, TAP2, or RGL2.  It is unclear whether these fusions 
generate chimeric proteins, whether they lead to functional inactivation of DAXX, 
or whether they retain ALT activity. However, it does suggest that the DAXX 
gene locus is susceptible to genetic rearrangements and that these 
rearrangements have the potential to drive cellular immortality through ALT in 
these cancers.     
The localization of the ATRX/DAXX complex to chromatin is critical for 
histone deposition and heterochromatin formation and defects in this process 
contribute to the activation and/or maintenance of ALT activity.  Here, we have 
defined a novel translocation in osteosarcoma that leads to defects in DAXX 
protein function despite maintaining a wild-type DAXX coding region.  To date, 
this fusion event has not been identified in any other cancer suggesting that this 
is a rare event.  The limited availability of osteosarcoma tumor samples and/or 
publicly available datasets containing next generation sequencing for 
osteosarcoma does not allow us to draw any significant conclusions on the 
frequency of this fusion event in this disease.  However, given the high level of 
genome instability and massive structural complexities in osteosarcoma our data 
argue that these tumors in particular should be analyzed using more 
comprehensive approaches combining next generation sequencing with 





Telomere maintenance in osteosarcomas frequently occurs via the ALT 
pathway and we show here that SLX4IP is inactivated in a subset of these 
tumors. Intriguingly, loss of SLX4IP is potentially mutually exclusive with loss of 
ATRX, DAXX and H3.3. (Table 2.1) However, since loss of SLX4IP is not 
sufficient to induce ALT-like phenotypes in ALT-negative cells, but its loss in 
ALT-positive cells augments telomere recombination, recent data suggest that 
like ATRX, loss of SLX4IP may contribute to the establishment or maintenance of 
ALT in combination with additional insults. Intriguingly, chromosomal aberrations 
involving SLX4IP are also frequently found in acute lymphoblastic leukemia 
(280–282). In particular, a site-specific monoallelic deletion within the 5' region of 
SLX4IP is found in 30% of childhood acute lymphoblastic leukemia in general 
and more than 60% of ETV6/RUNX1-rearranged acute lymphoblastic leukemia 
(281). Leukemias are not normally associated with a positive ALT status (199, 
204). However, in light of our findings it will be important to test whether these 
SLX4IP-deficient leukemias are ALT positive. Taken together, our findings further 
elucidate the genetics underpinnings of ALT activation, and highlight the need for 






CHAPTER THREE: RAD54 PROMOTES ALTERNATIVE LENGTHENING 
OF TELOMERES BY MEDIATING BRANCH MIGRATION 
Section 1: Abstract 
Cancer cells can activate the alternative lengthening of telomeres (ALT) 
pathway to promote replicative immortality. The ALT pathway promotes telomere 
elongation through a homologous recombination pathway known as break-
induced replication (BIR), which is often engaged to repair single-ended double-
stranded breaks (DSBs).  Single-ended DSBs are resected to promote strand 
invasion and facilitate the formation of a local displacement loop (D-Loop), which 
can trigger DNA synthesis, and ultimately promote telomere elongation. 
However, the exact proteins involved in the maturation, migration, and resolution 
of D-loops at ALT telomeres is unclear. In vitro, the DNA translocase RAD54 
both binds D-loops and promotes branch migration suggesting that RAD54 may 
function at ALT telomeres.  Here, we found that RAD54 is enriched at ALT 
telomeres. Although RAD54 does not regulate the formation of D-loops at ALT 
telomeres, it promotes telomeric DNA synthesis through its ATPase dependent 
branch migration. Loss of RAD54 leads to the formation of unresolved 
recombination intermediates at telomeres that form ultra-fine anaphase bridges 
in mitosis.  These data demonstrate an important role for RAD54 in promoting 




Section 2: Introduction 
Cancer cells must maintain telomere length in order to escape cellular 
senescence. The majority of cancer cells do so through reactivation of 
telomerase, however ~5-10% of cancers maintain telomere length in the absence 
of telomerase using the ALT pathway.(199, 202, 205, 206) ALT is a 
recombination-based pathway whereby one telomere uses either another 
telomere or extrachromosomal telomeric repeats as a template for elongation via 
BIR.(122, 152, 202, 206) BIR is the preferred pathway for repairing single-ended 
DNA DSBs genome-wide, a structure often formed following the collapse of 
irreversibly stalled replication forks. ALT cells undergo chronic replication stress, 
and consequently, exhibit high levels of spontaneous telomeric DNA 
damage.(63, 212, 238, 283) In addition to persistent DNA damage, ALT positive 
human cancer cells are described by several unique cellular phenotypes 
including heterogeneous telomere length, nuclear phase separated condensates 
called APBs, and C-rich extra-chromosomal telomeric repeats (C-circles).(202, 
204, 206, 209, 213) 
While telomere elongation via ALT has long been known to rely on 
homology directed repair, it was since demonstrated to specifically resemble BIR 
in mammalian cells. BIR at ALT telomeres can proceed via both RAD51-
dependent and RAD51-independent mechanisms to facilitate telomere 
elongation.(122, 123, 152) RAD51 functions to promote the search and capture 




function to stabilize replication forks during replication stress.(284) However, 
RAD51 is not essential for BIR at ALT telomeres as RAD52 may also function to 
promote the homologous pairing of DNA during ALT telomere elongation.(122, 
152, 248) Whether RAD51- or RAD52-dependent, the process of search and 
capture facilitates the formation of a jointed DNA structure called a displacement 
loop (D-loop), which functions as the platform for recruitment of DNA 
polymerases and the initiation of DNA synthesis. Synthesis events at ALT 
telomeres are thought to rely on the sequential recruitment of the DNA 
polymerases Polη and Polδ. (169) Polη has previously been shown to extend D-
loops in vitro,(285) providing evidence that Polη may function to initiate DNA 
synthesis. Following the initiation of DNA synthesis the POLD3 subunit of Polδ 
replaces Polη and synthesizes longer tracts of DNA to promote telomere 
extension events. (122, 169) These extended D-loops must then be processed to 
resolve the joint molecules and ensure completion of telomere elongation. 
Recombination intermediates formed at ALT telomeres must be processed 
prior to mitosis to maintain chromosomal stability.(120) The resolution of 
recombination intermediates at ALT telomeres proceeds either through 
nucleolytic cleavage by resolving enzymes such as the SMX complex (SLX1-4, 
MUS81-EME1, XPF-ERCC1), or through the migration of branched DNA 
structures leading to dissolution by the dissolvasome complex BTR (BLM, 
TOP3α, RMI1, RMI2).(73) It was recently described that SLX4IP binds to both 




ALT telomeres.(260) Resolution by nucleolytic cleavage generates cross-over 
events in the absence of net telomere elongation. Conversely, branch migration 
promotes DNA synthesis that, when followed by dissolution and/or cleavage, 
generates telomere extension events. Therefore, defining the enzymes involved 
specifically in branch migration dependent dissolution of D-loops at ALT 
telomeres will provide insight towards the regulation of elongation events at ALT 
telomeres and potentially identify novel therapeutic targets to inhibit telomere 
length maintenance in ALT positive cancers. 
RAD54 is a member of the RAD52 epistasis group and belongs to the 
SWI2/SNF2 family of ATPases. (106, 107) Early studies demonstrated that 
RAD54 is a DNA-dependent ATPase that translocates along dsDNA, suggesting 
a role for RAD54 in homologous recombination.  Generally, homologous 
recombination can be broken up into three main stages, the processing of DNA 
for the homology search (pre-synapsis), the formation of a mature D-loop 
(synapsis), and the dissolution or resolution of joint molecules (post-synapsis). 
Since the initial identification of RAD54, the biochemical activities of RAD54 have 
been studied extensively in vitro and demonstrate a range of functions for RAD54 
from pre-synapsis to post-synapsis during homologous recombination. (106, 107) 
During pre-synapsis, a broken DNA end is resected to form a 3’ single-
stranded overhang. This overhang is then bound by RAD51 to create a 
nucleoprotein filament that promotes strand invasion during the search for a 




with RAD51 to stabilize the RAD51 nucleo-protein filament and to stimulate 
strand invasion and the formation of the D-loop during synapsis. (100, 286) The 
ability of RAD54 to stimulate strand invasion relies on its ATPase activity, 
suggesting that RAD54 may function to regulate the accessibility of the template 
DNA, either by inducing topological changes (i.e. supercoiling), or facilitating 
nucleosome repositioning.(105) Once a homologous template has been found, 
RAD54 has been shown to disrupt the RAD51 nucleo-protein filament, promoting 
the removal of RAD51 and the subsequent conversion of a paranemic DNA joint 
into a fully synapsed plectonemic joint.(96, 97, 287) Thus, in vitro, RAD54 
functions to promote the formation, and/or synapsis, of a mature D-loop that is 
accessible to DNA polymerases and capable of being extended during 
homologous recombination. (101, 102, 288) 
In addition to the proposed roles for RAD54 during synapsis, data also 
suggest a role for RAD54 in post-synaptic processing of D-loops. RAD54 binds to 
branched recombination intermediates and promotes their branch migration in an 
ATPase-dependent manner.(289, 290) While RAD54 can bind and branch 
migrate many different DNA structures, it has highest affinity for partial-X 
junctions, the specific structure formed during BIR. (290, 291) The branch 
migration activity of RAD54 can dissolve recombination intermediate structures. 
Unlike other branch migrating enzymes, such as BLM and REQ1, RAD54 has 
been shown to be uniquely efficient at bypassing sites of DNA heterology. For 




between the invading strand and template DNA.(292) Together, these findings 
suggest that RAD54 not only regulates the formation and resolution of 
recombination intermediates, but that RAD54 may either compromise the fidelity 
of homologous recombination by promoting heterologous strand invasion events, 
or ensure fidelity by counteracting productive branch migration of heterologous 
recombination intermediates.  
Previous studies have demonstrated that RAD54 functions to regulate 
telomere length maintenance in murine cells,(293, 294) however, the contribution 
of RAD54 specifically to ALT mediated telomere elongation in human cancer has 
not yet been investigated. Given the role of RAD54 in regulating the formation 
and resolution of recombination intermediates, we asked whether RAD54 might 
also function at ALT telomeres to regulated BIR. Here, we demonstrate that 
RAD54 is recruited to telomeric DNA in response to DNA damage and functions 
to promote ALT activity via BIR. Depletion of RAD54 leads to a decrease in DNA 
synthesis at ALT telomeres. The ability of RAD54 to promote DNA synthesis at 
ALT telomeres was dependent on both its ATPase and branch migration 
activities.  Moreover, combined depletion of RAD54 and the resolvase enzyme 
SLX4 led to the formation of unresolved recombination intermediates visualized 
as ultrafine anaphase bridges in mitosis. Taken together, our data highlight a 
post-synaptic function for RAD54 during the dissolution of recombination 




Section 3: Methods 
siRNAs, cDNAs and primers 
All siRNA transfections were performed using Lipofectamine RNAiMax 
reagent in Opti-MEM.  siRNA was mixed with RNAiMax into Opti-MEM media 
and incubated for 15 minutes at room temperature before being added to cell 
culture media.  All plasmids were transfected using Fugene 6 transfection 
reagent. cDNA was mixed with Fugene 6 in Opti-MEM media and incubated for 
20 minutes at room temperature before being added to cell culture media.  Cells 
were plated 16-24 hours before Fugene transfection.  
Polη-GFP plasmid was a generous gift from Dr. Sharon Cantor.  GFP-
BLM plasmid was a gift from Nathan Ellis (Addgene plasmid #80070) N-myc-
TRF2 plasmid was a gift from Titia de Lange (Addgene plasmid #16066). WT-
RAD54 plasmid was a gift from Dr. Markus Lobrich and was then modified using 
InFusion cloning technique to introduce K189R, S49E and silent siRNA 
resistance mutations as was well as to move the gene insert into an pDEST-SFB 
backbone.  
ON-TARGETplus siRNAs were obtained from Dharmacon, siRAD54#1 
(AGAAUGAUCUGCUUCACUA) and siRAD54#2 
(CGAAUUACACCCAGACUUU), SLX4 
(GCUACCCGGACACUUGUCAUUGUUA),  





The following primers were used for RT-qPCR: 
GAPDH For(CAGAACATCATCCCTGCCTCTAC),  
GAPDH Rev(TTGAAGTCAGAGGAGACCACCTG),  
SLX4 For (TTGGTCCTACAGCGAATGCAG),  
SLX4 Rev (CATGTGCCGATGCTCCTACC) 
Antibodies and probes 
The following antibodies and probes were used where noted. BLM (Bethyl 
A300-110A), GAPDH (Santa Cruz sc-47724), GFP (Abcam, ab1218), mCherry 
(Takara 632543), MUS81 (Santa Cruz sc53382), myc (ThermoFisher MA1-980), 
PCNA (Cell Signaling Technology, 13110S), PICH (Millipore 04-1540), PML 
(Santa Cruz sc-5621), PML (Santa Cruz sc-966), RAD51 (Santa Cruz sc-8349, 
IF), RAD51 (Abcam ab176458, ChIP and western blot), RAD54 (Santa Cruz sc-
374598), TRF1  (Millipore 04-638), TRF2 (Millipore 05-521), Tubulin (Cell 
Signaling Technology 2125S) 
The following probes were obtained from Invitrogen and used for dot blots 
where noted:  
Telomere probe (CCCTAA)4,  
Alu repeat probe (GTGATCCGCCCGCCTCGGCCTCCCAAAGTG) 







HeLa 1.2.11, U2OS, U2OS-TRF1-FOK1-WT and U2OS-TRF1-FOK1-
D450A were cultured in DMEM, 10% FBS, 1% penicillin/streptomycin.  HuO9, 
NOS1 and SJSA1 were cultured in RPMI-1640, 5% FBS, 1% 
penicillin/streptomycin, 1% sodium pyruvate.  Cal72 was cultured in DMEM/F12, 
10% FBS, 1% penicillin/streptomycin.  SaOS2 was cultured in RPMI-1640, 10% 
FBS, 1% penicillin/streptomycin.  All cells were grown at 37°C in a humidified 
incubator with 5% CO2.  U2OS-TRF1-FOK1 cells were obtained as a gift from Dr. 
Roger Greenberg.  These cells were treated where indicated with doxycycline 
(Sigma D9891), (Z)-4-hydroxytamoxifen (Sigma H7904) and Shield1 (Takara 
632189). 
Cell cycle analysis 
Cells were harvested and washed with PBS prior to overnight fixation in 
70% ethanol at -20°C.  The following day, cells were pelleted and washed twice 
with PBS. RNA was digested with RNAse A (250 µg/mL) at 37°C for 30 minutes.  
Propidium iodide (Sigma) was diluted to 50 µg/mL in PBS, then added 1:1 to 
cells.  Cells were incubated with propidium iodide for at least 10 minutes in the 
dark. Cells were analyzed on BD FACS Calibur. At least 10,000 events were 
collected.  Cells were gated to remove doublets and debris.  Cell cycle profile 





Western blots were performed using standard protocols.  Briefly samples 
were lysed in 2X sample buffer at 95°C for 15 minutes.  Soluble protein lysates 
were run on SDS-PAGE and transferred onto PVDF membranes.  Membranes 
were blocked in TBS-T (1X TBS, 0.1% Tween-20) containing 5% dry non-fat 
milk.  Membranes were incubated overnight at 4°C in primary antibody diluted in 
5% milk in TBS-T.  Following overnight incubation, membranes were washed 3 
times with TBS-T for 5 minutes each at room temperature, then incubated with 
horseradish peroxidase conjugated secondary antibodies diluted in 5% milk in 
TBS-T.  Following secondary, membranes were washed 3 x 5 minutes and then 
visualized using enhanced chemiluminescence reagents from BioRad.  
Combined immunofluorescence and DNA FISH 
Combined immunofluorescence and DNA FISH was performed as 
previously described.(273) Cells were washed twice with PBS for 5 minutes 
each.  The cells were then treated with cytobuffer (100 mM NaCl, 300 mM 
sucrose, 3mM MgCl2, 10 mM PIPES pH 7, 0.1% Triton X-100) for 7 minutes at 
4°C.  Cells were next rinsed with PBS and fixed with 4% paraformaldehyde in 
PBS for 10 minutes at room temperature. For PCNA staining, fixation was 
instead performed with cold methanol at -20°C for 10 minutes. To permeabilize 
the cells, 0.5% NP40 in PBS was used for 10 minutes at room 
temperature.  Following a PBS rinse, cells were blocked for 1 hour at room 




with primary antibody diluted in PBG overnight at 4°C.  The cells were washed 
three times with PBS for 5 minutes each at room temperature, and then 
incubated with secondary antibody diluted in PBG for 45 minutes at room 
temperature in the dark.  After this incubation the cells were washed three times 
with PBS for 5 minutes each and then fixed with 4% paraformaldehyde in PBS 
for 10 minutes at room temperature.  Cells were then digested with RNaseA 200 
µg/mL in 2X SSC for 30 minutes at 37°C.  A series of ethanol washes (70%, 
85%, 100%) for 2 minutes each at room temperature was used to dehydrate the 
cells.  The coverslips were then dried at 37°C for 20 minutes.  Telomere probe 
(PNA-(CCCTAA)4 Tel-Cy3) diluted 1:750 in hybridization buffer (70% formamide, 
0.25% blocking reagent [Roche], 10mM Tris pH 7.5, 4.1 mM Na2HPO4, 1.25 mM 
MgCl2, 0.45 mM citric acid).  Slides were incubated with probe and denatured at 
85°C for 3 minutes, then placed in a humidified chamber at 37°C overnight.  
Coverslips were washed with 2X SSC and formamide mixed 1:1 three times for 5 
minutes each at 37°C, and then three times in just 2X SSC at 37°C.  1 µg/mL 
DAPI was added into 2X SSC for a final 10 minute wash at room temperature. 
Coverslips were mounted on glass slides using vectashield mounting medium. 
Polη IF-FISH 
Cells grown on coverglass were washed with PBS, and then fixed with 4% 
paraformaldehyde for 30 minutes at room temperature.  After washing with PBS, 
cells were permeabilized with 0.5% Triton-X in PBS for 15 minutes. Primary 




PBS.  Cells were stained with primary antibody overnight.  Cells were washed 3 
times for 5 minutes each with PBS, and then incubated with secondary antibody 
diluted in 3% BSA, 0.05% Tween-20 in PBS for 1 hours at room temperature.  
Following secondary antibody, the staining protocol is identical to the standard 
IF-DNA FISH protocol.  
EdU incorporation and DNA FISH 
Cells were grown on coverglass and pulsed with 10µM EdU (5-ethynyl-2’-
deoxyuridine) in normal cell culture conditions for 1.5 hours immediately prior to 
staining.  Coverslips were washed with PBS, then incubated with cytobuffer (100 
mM NaCl, 300 mM sucrose, 3mM MgCl2, 10 mM PIPES pH 7, 0.1% Triton X-
100) for 7 minutes at 4°C. Following a PBS wash, cells with fixed with 4% 
paraformaldehyde for 10 minutes at room temperature.  Coverslips were washed 
with PBS and then permeabilized with 0.5% NP40 in PBS for 10 minutes at room 
temperature.  Cells were wash twice for 5 minutes each with PBS prior to Click-It 
reaction labeling.  Click-it chemistry was performed according to manufacturer’s 
instructions. Coverslips were incubated in 10µM AlexaFluor488 Azide 
(ThermoFisher) diluted in 100mM Tris pH 8.5, 1mM CuSO4, 100mM ascorbic 
acid, 30 minutes at room temperature in the dark.  Coverslips were washed 3 
times for 5 minutes each in 1X TBS + 0.2% Triton X-100 at room temperature. 
When combined with FISH, the FISH protocol above was followed, beginning 






Genomic DNA was purified using QiaAMP DNA mini kit according to 
manufacturer’s instructions.  DNA was digested overnight with Alu1 and Mbo1 
restriction enzymes and then purified using Qiagen PCR purification kit.  The 
DNA was diluted and quantified using a nanodrop spectrophotometer.  80 ng of 
gDNA was diluted in 25 µl of 1X Φ29 buffer (NEB) containing BSA (NEB; 0.08 
mg/ml), 0.1% Tween, 0.25 mM each dATP, dGTP, dTTP.  Samples were 
incubated in the presence (+Φ29) or absence (-Φ29) of 7.5 U Φ29 polymerase 
(NEB) at 30°C for 8 hrs, then 65°C for 20 minutes. 
Rolling circle amplification products were boiled in 10X SSC and then run 
through a BioRad vacuum dot blot manifold onto Hybond N+ membrane. The 
membrane was UV crosslinked for 35s (125J), and then pre-incubated in Ultra-
Hyb hybridization buffer (Ambion) for 1 hr at 50°C.  Telomere probe (CCCTAA)4 
was labeled with digoxigenin using the DIG oligonucleotide 3’-end labeling kit  
(Roche) according to manufacturer’s instructions.  Labeled probe was diluted 
1:1000 into hybridization buffer and membrane was incubated at 50°C overnight.  
The membrane was washed twice, 5 minutes each at room temperature with 2X 
SSC + 0.1% SDS, and then twice 15 minutes each at 50°C in 0.5X SSC + 0.1% 
SDS. The membrane was then prepared and developed using the DIG Wash and 
Block Buffer set (Roche), anti-DIG-AP (Roche) and CDP-Star (Roche) according 
to manufacturer’s instructions. Membrane was developed using BioRad 





Cells were crosslinked in 1% formaldehyde for 8 minutes at room 
temperature.  Crosslinking was stopped by adding glycine, diluted to 0.125M for 
5 minutes at room temperature.  Cells were washed twice with ice cold PBS, and 
then collected.  Cells were lysed in cellular lysis buffer (5 mM PIPES, 85 mM KCl, 
0.5% NP-40, protease inhibitor) for 5 minutes on ice, and then spun down at 60 x 
g for 5 minutes. Supernatant was removed, and pellet was lysed with nuclear 
lysis buffer (50mM Tris pH 8, 10mM EDTA pH 8, 0.2% SDS, protease inhibitor) 
at 4°C.  Chromatin samples were sonicated (30 sec on/20 sec off) in a QSonica 
water bath sonicator at 4°C for 90 minutes, to generate chromatin fragments 
between 150-500 base pairs. Sonicated chromatin samples were spun down at 
full speed, 4°C for 10 minutes, and supernatant was collected.  
Chromatin samples (300µg) were diluted 9-fold in dilution IP buffer (16.7 
mM Tris pH 8, 1.2 mM EDTA, 167 mM NaCl, 0.01% SDS, 1.1% Triton X-100, 
protease inhibitor), and incubated with antibody (4µg) overnight at 4°C.  Inputs 
were removed from sonicated chromatin sample and stored separately.  Washed 
Protein A or protein G magnetic dynabeads were added into IP mixture for the 
final 2 hours. Beads were washed for 3-4 minutes each at room temperature with 
the following buffers: twice with dilution IP buffer, once with TSE buffer (20 mM 
Tris pH 8, 2mM EDTA pH 8, 500 mM NaCl, 1% Triton X-100, 0.1% SDS), once 
with LiCl buffer (100mM Tris pH 8, 500 mM LiCl, 1% sodium deoxycholate, 1% 




the same for the remainder of protocol.  Samples were incubated in elution buffer 
(50mM NaHCO3, 140 mM NaCl 1% SDS) containing 67µg/mL proteinase K for 1 
hour at 55°C.  Beads were removed from eluted samples using a magnet, and 
the supernatants were collected, and incubated overnight at 65°C.  Samples 
were treated with 1.2 mg/mL RNAseA for 30 minutes at 37°C, then samples were 
cleaned up using a Qiagen PCR purification kit, eluting in water.   
Samples were boiled for 5 minutes at 95°C, then diluted to 10X SSC and 
run through a BioRad vacuum dot blot manifold onto Hybond N+ membrane to 
detect telomeric DNA using dot blot. The membrane was UV crosslinked for 35s 
(125J), and then pre-incubated in Ultra-Hyb hybridization buffer (Ambion) for 1 hr 
at 50°C.  Telomere probe (CCCTAA)4 was labeled with digoxigenin using the 
DIG oligonucleotide 3’-end labeling kit  (Roche) according to manufacturer’s 
instructions.  Labeled probe was diluted 1:1000 into hybridization buffer and 
membrane was incubated at 50°C overnight.  The membrane was prepared and 
developed using the DIG Wash and Block Buffer set (Roche), anti-DIG-AP 
(Roche) and CDP-Star (Roche) according to manufacturer’s instructions. 
Following detection using the (CCCTAA)4 telomeric probe, blot was stripped by 
boiling 0.1% SDS in water, and incubating membrane in solution for 15 minutes.  
The membrane was then reprobed using a DIG-labeled probe specific to Alu 
repeats and developed using the DIG Wash and Block Buffer set (Roche), anti-





Detecting ultrafine anaphase bridges 
Cells were grown on coverglass to 80-90% confluence, agitation was 
avoided as much as possible throughout the protocol.  Cells were washed gently 
with PBS.  Pre-extraction buffer A (0.2% Triton in 1X PEM buffer [20mM PIPES 
pH 6.8, 1 mM MgCl2, 10 mM EGTA])  was added to PBS on coverslips, diluting 
the buffer 1:1 in PBS.  Cells were incubated for 60 seconds at room temperature.  
Pre-extraction buffer B (0.1% triton, 8% PFA in 1X PEM) was added directly into 
Pre-extraction A buffer/PBS mixture, diluting Pre-extraction buffer B 1:1. Cells 
were incubated for 15 minutes at room temperature. Cells were washed 3 times 
for 5 minutes each with PBS.  Coverslips were incubated at 4°C overnight in 
PBSAT (3% BSA, 0.5% triton in 1X PBS). 
Coverslips were then incubated with primary antibody diluted in PBSAT 
overnight at 4°C in a humidified chamber.  After primary antibody, coverslips 
were washed with PBSAT 3 times for 10 minutes each at room temperature.  
Secondary antibody was diluted in PBSAT, and cells were incubated with 
secondary antibody for 2 hours at room temperature.  Coverslips were washed 3 
times for 15 minutes each with PBSAT, then for 10 minutes with PBS.  To 
stabilized staining, antibodies were fixed with post-staining fixation buffer (4% 
PFA in 1X PBS) for 5 minutes at room temperature.  Coverslips were washed 3 
times for 5 minutes each with PBS, followed by a 5 minute incubation with DAPI 
diluted in PBS.  Cells were washed a final time with PBS, followed by a rinse with 




RT-qPCR analysis of gene expression 
Cells were harvested, washed and pelleted.  RNA was extracted using 
Qiagen RNeasy mini kit according to manufacturers instructions.  500 ng of RNA 
was reverse transcribed using SuperScript IV (ThermoFIsher) according to 
manufacturer’s instructions.  cDNA was diluted 1:10 into qPCR reaction with 
PowerUP SYBR green master mix, and 10µM reverse primer and 10µM forward 
primer.  qPCR was performed on a StepOne qPCR machine using the following 
program: 50°C 2 min, 95°C 2 min, then 40 cycles (95°C 15s, 60°C 15 s, 72°C 1 
min), followed by a standard melt curve. Data were analyzed by ΔΔCT method, 
corrected to GAPDH and mock sample. Samples were run in technical triplicate. 
Statistical Analysis 
Experiments were performed at least 3 times independently. Statistical 
analysis was performed using GraphPad Prism8 software. Exact p-values are 
given for each test, and results were considered significant if p-values were < 
0.05. 
 
Section 4: Results and Discussion 
RAD54 localizes to ALT telomeres and responds to telomeric DNA damage 
Given the crucial role of RAD54 in homology directed repair processes in 
eukaryotic cells, we asked whether RAD54 functions at ALT telomeres to 




determined whether RAD54 associated with telomeres in a panel of unperturbed 
human cancer cell lines using combined immunofluorescence (IF) and DNA 
fluorescence in situ hybridization (FISH). Here, using IF-FISH we demonstrate 
that RAD54 colocalized with telomeric DNA across a panel of ALT positive 
osteosarcoma cell lines. Moreover, the colocalization between RAD54 and 
telomeric DNA was enriched in ALT positive cells as compared to the 
colocalization events in telomerase positive cells. (Fig 3.1A–B) In ALT cells 
telomeres are heterogeneous in length, including very long telomeres that can 
exacerbate replication stress.(202) The observed enrichment of RAD54 at ALT 
telomeres was not simply a consequence of the extended length of ALT 
telomeres as we were unable to detect RAD54 at telomeric DNA in the HeLa 
1.2.11 (HeLa LT) cell line that maintain long telomeres. (Fig 3.1A-B) Given that 
ALT telomeres are frequently associated with DNA repair factors in APBs,(209) 
we asked whether the accumulation of RAD54 at ALT telomeres was specific to 
APBs.  In fact, we found that the majority of RAD54 foci detected by IF in ALT 
cells colocalized with telomeres in APBs, (Fig 3.1C-D) suggesting that RAD54 
may be contributing to the ALT mechanism.  
ALT telomeres are associated with replication stress and spontaneous 
DNA damage.  Therefore, we asked whether RAD54 was recruited to ALT 
telomeres in response to DNA damage.(122, 152) To test this, we first treated 
ALT cells with the topoisomerase inhibitor camptothecin (CPT) to induce the 




formation and a significant enrichment of RAD54 at ALT telomeres. (Fig 3.2A-B) 
Given that CPT induces DNA damage throughout the genome, we asked 
whether we could further enhance RAD54 recruitment to ALT telomeres by 
inducing DNA damage specifically at the telomeres.  Here, we generated DSBs 
at telomeric DNA by inducing expression of the chimeric TRF1-FOK1 
protein.(122, 123) Following incubation with doxycycline and tamoxifen, we could 
detect the expression of TRF1-FOK1-mCherry protein by Western blot. (Fig 
3.1E) Moreover, expression of TRF1-FOK1-mCherry led to an obvious increase 
in telomeric foci size measured by FISH, indicative of the formation of telomeric 
DNA DSBs and subsequent telomere clustering events.(123) Following 
expression of TRF1-FOK1-mCherry we also observed a significant increase in 
the number of RAD54 foci at telomeric DNA and a significant increase in the 
percentage of cells containing 8 or more RAD54 foci that colocalized to telomeric 
DNA. (Fig 3.1F-H) In contrast, expression of TRF1 fused to the nuclease dead 
FOK1 mutant protein (D450A) caused no change in the localization of RAD54 to 
telomeres. (Fig 3.1F-H) Together, these data demonstrate that RAD54 is 
localized at ALT telomeres, and this localization is enriched in response to DNA 






Figure 3.1 – RAD54 localizes to ALT telomeres in response to DNA damage. 
A) Combined IF and DNA FISH analysis of RAD54 (IF) and telomeres (FISH). White arrows 
indicate RAD54 foci that colocalize with telomeres.  Scale bars = 10 µm 
B) Quantification of data in A. A cell was counted positive if it contained ≥1 colocalization 
between RAD54 and the telomere.  >100 cells counted per cell line per repeat. mean±sd 
C) Combined IF and DNA FISH analysis of RAD54 (IF), PML (IF) and telomeres (FISH) in ALT 
cell lines SaOS2 and HuO9. Scale bars = 10 µm 
D) Quantification of HuO9 data from C. RAD54 foci were detected using particle analysis in Fiji. 
Total RAD54 foci were counted. RAD54 foci were considered in APBs if they colocalized with 
both PML and telomere.  At least 100 cells counted per repeat, n = 3. mean±sd 
E) Western blot for TRF1-FOK1-mCherry fusion protein following treatment with 40 ng/mL 
doxycycline for 16 hrs and then 1µM Shield-1 and 1µM 4-OHT for 4 hrs 
F) Combined IF and DNA FISH for RAD54 (IF) and telomeres (FISH) in U2OS-TRF1-FOK1-WT 
or U2OS-TRF1-FOK1-D450A (nuclease dead) cells.  Cells were treated as in E  
G) Quantification of data from F. RAD54 foci were detected using particle analysis in Fiji.  At 
least a total of 300 cells were counted from 3 repeated experiments. mean±sem.  Values 
were compared using Kruskal-Wallis test followed by Dunn’s multiple comparison test.   
H) Quantification of data from F.  RAD54 foci were detected using particle analysis in Fiji.  Cells 
were counted as positive if they counted 8 or more RAD54 foci that colocalized with 
telomeres.  Values shown are mean±sem.  Values were compared using standard two-way 


















































































































































Figure 3.2 – Genome-wide DNA damage enriches RAD54 at telomeres. 
A) Combined IF and DNA FISH for RAD54 and telomeres in SaOS2 treated with vehicle 
(DMSO) or camptothecin (CPT) 1µM for 1 hr immediately prior to staining.   
B) Quantification of A. A cell was counted as positive if it contained at least 1 colocalization 
event between RAD54 and telomere. At least 100 cells were counted per repeat, n=3. Values 


















































RAD54 is dispensable for synapsis at ALT telomeres 
Previous studies suggest both a pre-synaptic and a post-synaptic role for 
RAD54 in the regulation of homologous recombination.(289–291, 295) Pre-
synaptically, RAD54 has been demonstrated to regulate RAD51 nucleoprotein 
filament formation and stability.(96, 98–100, 107, 296) Given that BIR at ALT 
telomeres has been demonstrated to promote telomere elongation via both 
RAD51-dependent and RAD51-indepdent mechanisms,(122, 123) we asked 
whether RAD54 functioned to regulate RAD51 at ALT telomeres. Depletion of 
RAD54 by siRNA in ALT cell lines did not lead to statistically significant changes 
in the localization of RAD51 to ALT telomeres as measured by combined IF-
FISH. (Fig 3.3A-B) Likewise, loss of RAD54 did not affect the localization of 
RAD51 to telomeric DNA by chromatin immunoprecipitation (ChIP, Fig 3.3C-E, 
Fig 3.4D). Given the known interaction between RAD51 and RAD54 at sites of 
RAD51-mediated synapsis,(96) we also wanted to determine whether RAD51 
was involved in recruiting RAD54 to possible sites of D-loop formation at ALT 
telomeres. We found that depletion of RAD51 did not affect RAD54 localization to 
ALT telomeres, (Fig 3.4A-C) suggesting that RAD51 is not essential for RAD54 
function at ALT telomeres. 
PCNA recruitment to ALT telomeres is an early event in the ALT 
mechanism, recruiting DNA polymerases and establishing a platform for post-
synaptic DNA synthesis events at ALT telomeres.(122) Expanding on previous 




is found across a panel of ALT positive cells. (Fig 3.4E-F) Loss of RAD54 did not 
prevent PCNA recruitment to ALT telomeres, (Fig 3.4G-H) and in fact caused a 
significant increase in PCNA recruitment to telomeres in at least one ALT positive 
cell line, further indicating that RAD54 is not regulating early events in the BIR 
mechanism at ALT telomeres. 
DNA strand invasion and synapsis promotes the formation of a 
plectonemic DNA molecule. This plectonemic structure is required to ensure 
polymerase binding, facilitate DNA synthesis at the displacement loop (D-loop), 
and ensure elongation of the invading strand.(101) While the POLD3 subunit of 
Polδ is recruited by PCNA in order to synthesize long tracts of DNA at ALT 
telomeres,(122, 169) Polη is thought to initiate DNA synthesis during ALT 
telomere elongation with short tracts of DNA.(169, 285) RAD54 has been 
demonstrated to regulate the formation of the mature plectonemic D-loop and, 
ultimately, promote DNA synthesis at the 3’ end of the invading strand.(96, 101) 
However, whether loss of RAD54 leads to defects in either the recruitment of 
and/or initiation by Polη during BIR has not been investigated.  As a surrogate for 
the formation of mature D-loops, we analyzed the recruitment of Polη-GFP to 
telomeric DNA by IF-FISH. Given that overexpression of Polη can be toxic in 
cells,(169) we only scored cells positive for GFP expression. Here, we 
demonstrate that loss of RAD54 did not lead to a significant change in the 
percentage of GFP-positive cells that contained colocalization of Polη-GFP foci 




Figure 3.3 – RAD54 is dispensable for synapsis at ALT telomeres. 
A) Combined IF and DNA FISH for RAD51 (IF) and telomeres (FISH).  Cells were transfected 
with 20nM siRAD54#2 for 48 hours. Scale bars = 10 µm 
B) Quantification of B.  A cell was counted as positive it is contained ≥1 colocalization event 
between RAD51 and telomeres.  >100 cells counted per condition per repeat, n=3. mean±sd.  
Data compared using standard two-way ANOVA and Sidak’s multiple comparison test. 
C) ChIP for telomeric DNA associated with RAD51.  DNA dot blot probed with DIG labeled 
telomere or Alu probe.  HuO9 cells were transfected with 20nM siRAD54 #2, or 15µg myc-
TRF2 for 72 hours prior to immunoprecipitation with RAD51 antibody (Mock, siRAD54 
conditions) or myc antibody (myc-TRF2 positive control). 
D) Quantification of (CCCTAA)4 dot blot performed in C. (IP/input) were normalized to mock 
control. mean±sd, n=3.  Values were compared using two-tailed unpaired student’s t-test. 
E) Western blot of samples used for ChIP in C-D.  
F) Combined IF and DNA FISH for GFP (IF) and telomeres (FISH) .  Cells were forward 
transfected with Polη-GFP, and then after 24 hours transfected with 20nM siRAD54#2. Cells 
were stained for GFP and telomeres 48 hours after siRNA transfection.  Scale bars = 10 µm 
G) Quantification of data in F. GFP negative cells were excluded from analysis. Cells were 
positive if they showed 1 or more colocalization events between GFP (Polη) and telomeres.  
At least 50 GFP positive cells were counted per condition per repeat, n=3. mean±sd. Values 








































































































































Figure 3.4 – RAD54 is dispensable for early synaptic events at ALT telomeres. 
A) Representative image from combined IF and DNA FISH for RAD54 at telomeres in HuO9 
cells treated with 20nM siRAD51 for 48hrs. Scale bars = 10 µm 
B) Quantification of data from A. Cells were counted positive if they had at least 1 colocalization 
event between RAD54 and telomeres.  At least 100 cells per condition were counted per 
repeat. mean±sd, n=3. Values were compared using unpaired two-test student’s t-test.   
C) Western blot from samples used in EV2 A-B.  
D) Western blot of RAD51 immunoprecipitation from HuO9 cells.  Blot was probed for RAD51.  
Asterisk indicates non-specific band in IgG pull down. 
E) Quantification of focal accumulation of PCNA at telomeres across a panel of ALT and non-
ALT cell lines.  Cells were counted positive if they had at least 1 PCNA foci that colocalized 
with telomeres.  Pan-nuclear staining was excluded.  At least 100 cells were counted per cell 
line per repeat. Values shown are mean±sd, n=3. 
F) Data from EV2 D graphed according to ALT status.  Each dot represents the mean value for 
one cell line. mean±sd. Data were compared using unpaired two-tailed student’s t-test. 
G) Representative images from combined IF and DNA FISH for PCNA at telomeres in HuO9 or 
SaOS2 treated with 20nM siRAD54#2 for 48 hours. Scale bars = 10 µm 
H) Quantification of data from F. HuO9 or SaOS2 treated with 20nM siRAD54#1 or 20nM 
siRAD54#2 for 48 hours Data were quantified as in EV2 D. mean±sd, n=3. Values were 














































































































































































required for formation of the mature plectonemic joint nor for recruitment of Polη 
to ALT telomeres during BIR-mediated telomere elongation.  Together these data 
demonstrate that RAD54 does not function to regulate synapsis during BIR at 
ALT telomeres. 
RAD54 promotes ALT activity 
Polη initiation is followed by long-range DNA synthesis and productive 
elongation by POLD3.(122, 169) While the recruitment of Polη was unaffected by 
loss of RAD54, we were curious whether long-range synthesis remained intact. 
Therefore, we analyzed EdU incorporation at ALT telomeres using Click-it 
chemistry combined with telomere FISH to visualize nascent synthesis events at 
the telomeres.(238, 251, 283) To exclude S-phase DNA synthesis events, we 
only scored cells that lacked pan-nuclear EdU staining or contained fewer than 8 
EdU foci. RAD54 depletion led to a significant reduction in EdU incorporation 
events that colocalized with the telomeric DNA without altering cell cycle 
progression, (Fig 3.5A-B, Fig 3.6A, C) indicating that RAD54 promotes nascent 
telomere repeat synthesis at ALT telomeres.  
The defects in DNA synthesis following RAD54 depletion suggest that 
RAD54 functions to promote ALT activity. Therefore, we asked whether RAD54 
depletion would also lead to a decrease in other hallmarks of ALT activity. 
RAD54 depletion by siRNA in ALT positive cancer cells led to a significant 
decrease in the C-rich extrachromosomal telomeric repeat DNA (C-circles).(297) 




byproduct of the recombination reaction at ALT telomeres(204, 213).  To 
determine whether this decrease in C-circles correlated with an increase in 
unresolved recombination intermediates we analyzed APB formation. APBs are 
induced by DNA damage and colocalize with DNA damage repair factors leading 
to the speculation that APB function as platforms for the recombination of ALT 
telomeres. (209, 251) Moreover, APBs are increased in the absence of key repair 
enzymes, suggesting that defects in the resolution of DNA damage may lead to 
the accumulation of APBs. (73, 260) Likewise, we found that loss of RAD54 led 
to a modest, yet significant increase in APB positive cells, supporting the idea 
that loss of RAD54 leads to an increase in stalled or irreparable recombination 
intermediates. (Fig 3.5E-F)  
RAD54 branch migration promotes DNA synthesis at ALT telomeres 
Branch migration of the mature D-loop, including extension and dissolution 
of the resulting recombination intermediate, is a post-synaptic event in BIR. 
RAD54 is a DNA translocase that relies on its ability to both oligomerize and 
hydrolyze ATP to promote branch migration.(289, 290, 296, 298) Oligomerization 
of RAD54 is regulated through a phosphorylation event on the N-terminal domain 
at Serine-49.(122) CDK2 phosphorylation of S49 inhibits the oligomerization and 
subsequent branch migration of RAD54, leaving other RAD54 functions intact, 
such as its ability to bind to DNA and stimulate RAD51-mediated strand 
invasion.(122) By overexpressing an siRNA resistant RAD54 construct, (Fig 




Figure 3.5 (Part I) – RAD54 oligomerization and ATPase activity regulate break-induced 
replication at ALT telomeres. 
A) Representative images of combined EdU staining (Click-it) and DNA FISH for telomeres. 
Cells were transfected with 20nM siRAD54#2 for 48 hours followed by a 1.5 hr pulse of EdU. 
Pan-nuclear EdU stain represents S-phase cells.  White arrows indicate non-S-phase cells 
containing EdU colocalizing with telomeres. Scale bars = 10 µm 
B) Quantification of data shown in A. Cells were mock transfected or transfected with 20nM 
siRAD54#1 or 20nM siRAD54#2 for 48 hours followed by a 1.5 hr pulse of EdU.  Cells with 
pan-nuclear EdU signal or greater than 8 EdU foci were excluded from analysis as S-phase 
cells.  Non-S-phase cells were considered positive if they contained at least one EdU foci 
colocalizing with telomeres.  Data were normalized to mock condition for each repeat.  At 
least 100 non-S-phase cells were counted per condition per repeat, n=3. mean±sd. Data 
were analyzed by two-way ANOVA and Dunnett’s multiple comparison test.   
C) Representative DNA dot blot from C-circle assay on HuO9 cells, either mock transfected or 
transfected with 20nM siRAD54#2 for 48 hours.  
D) Quantification of C-circle assay in A.  Signal was quantified with densitometry, background (- 
Φ29) was subtracted and signal was normalized to mock.  N=5, values shown are mean±sd.  
Conditions were analyzed using unpaired two-tailed student’s t-test.   
E) Representative images of combined IF and DNA FISH for PML (IF) and telomeres (FISH). 
Cells were mock transfected or transfected with 20nM siRAD54#2 for 48 hours.  White 
arrows indicate large colocalization events.  Blue arrows indicate small colocalization events.  
F) Quantification of E.  Cells were considered positive if they contained 1 large or 3 small 
colocalization events.  At least 100 cells were counted per condition per repeat, n=3. 
mean±sd. Data were analyzed using two-way ANOVA followed by Dunnett’s multiple 








































































































































































































































Figure 3.5 (Part II) – RAD54 oligomerization and ATPase activity regulate break-induced 
replication at ALT telomeres. 
A) Representative images of combined EdU staining (Click-it) and DNA FISH for telomeric DNA.  
HuO9 cells were forward transfected with 2µg empty vector (EV), RAD54-WT, RAD54-
K189R, or S49E construct.  After 24 hours, cells were transfected with 20 nM siRAD54#2 for 
48 hours followed by a 1.5 hr pulse of EdU. White arrows indicate non-S-phase cells 
containing EdU colocalizing with telomeres. Scale bars = 10 µm 
B) Quantification of data shown in G. Non-S-phase cells were considered positive if they 
contained at least one EdU foci colocalizing with telomeres.  Data were normalized to EV-
Mock condition for each repeat.  At least 100 non-S-phase cells were counted per condition 
per repeat, n=4 for EV, WT, S49E, n=3 for K189R.  Values shown are mean±sd. Data were 











































































































































































































































































































































































































































































Figure 3.6 – RAD54 regulates ALT activity without altering cell cycle. 
A) Representative western blot for RAD54 on HuO9 and SaOS2 cells treated with 20 nM 
siRAD54#1 or siRAD54 #2 for 48 hours.  
B) Representative western blot for RAD54 on samples from G-H.  Overexpressed RAD54 runs 
as a doublet. Top band is expected molecular weight of SFB-RAD54, *indicates band that is 
a cleavage product of overexpressed RAD54. Tubulin used as a loading control.   
C) Cell cycle profile of HuO9 cells mock transfected, treated with 20nM siRAD54 #2 for 48 
hours, or treated with 1µM colcemid for 16 hours.  
D) Representative images of IF-DNA FISH showing RAD54 at the telomeres using SFB-RAD54 
constructs and siRAD54#2.  HuO9 cells were forward transfected with 2µg empty vector 
(EV), RAD54-WT, RAD54-K189R, or S49E construct.  After 24 hours, cells were transfected 










































































RAD54 depletion, as measured by EdU incorporation events. (Fig 3.5G-H) In 
contrast, neither the ATPase dead RAD54 mutant (K189R)(104) nor the 
phosphomimetic RAD54 mutant (S49E)(298) of RAD54 were able to rescue the 
EdU incorporation defect caused by RAD54 depletion. (Fig 3.5G-H) These data 
demonstrate that RAD54 oligomerization and ATPase activity are critical for 
branch migration of the mature D-loop further highlighting a role for RAD54 in the 
post-synaptic regulation of BIR at ALT telomeres.  
RAD54 limits the formation of ultra-fine anaphase bridges at ALT telomeres 
It was previously suggested that the recombination intermediates formed 
during BIR at ALT telomeres are processed either by the BTR complex (BLM, 
TOP3A, RMI1/2) to promote dissolution and telomere elongation events, or by 
the SMX resolvasome (SLX1-4, MUS81-EME1, XPF-ERCC1) to promote 
cleavage and cross-over events without elongation.(73, 169) If loss of RAD54 led 
to the formation of unresolved recombination intermediates, we would expect to 
see an increase in the recruitment of resolving enzymes to these sites of 
recombination to process the joint molecules prior to mitosis. Therefore, we 
specifically analyzed the recruitment of BLM and MUS81 to telomeres following 
RAD54 knockdown by IF-FISH. RAD54 depletion led to a modest decrease in 
BLM recruitment to ALT telomeres in interphase cells, (Fig 3.7A-C) yet a 
significant increase in MUS81 at ALT telomeres, (Fig 3.7D-E) suggesting that 





Progression into mitosis with unresolved branched DNA structures formed 
from recombination intermediates can lead to the formation of ultra-fine 
anaphase bridges (UFBs) and ultimately, DNA breaks and genome 
instability.(120, 299) UFBs, including those formed as a result of unresolved 
homologous recombination joints (HR-UFBs), are coated by the PICH (PLK1-
interacting checkpoint helicase) protein and can be detected in anaphase using 
PICH specific antibodies.(120) It has previously been shown that depleting both 
the dissolvase (i.e. siBLM) and resolvase (i.e. siSLX4) branches of BIR resolution 
led to an increase in telomeric bridges.(73) Given that loss of RAD54 leads to an 
increase in the recruitment of components of the SMX resolvasome to ALT 
telomeres (Fig 3.7D-E), we hypothesized that combined depletion of RAD54 and 
SLX4 would lead to an increase in UFB formation. Here we show that similar to 
the combined depletion of BLM and SLX4, combined depletion of RAD54 and 
SLX4 in ALT positive cells leads to an increase in UFBs and an increase in the 
number of bridges per anaphase. (Fig 3.7F-H, Fig 3.8A-B) When BLM, RAD54 
and SLX4 were all simultaneously depleted, there was no additional increase in 
bridge formation or the number of bridges per anaphase, indicating that BLM and 
RAD54 may be working in the same pathway to promote resolution of 
recombination intermediates. (Fig 3.7F-H) Depletion of each enzyme individually 
did not lead to an increase in UFB formation (Fig 3.7F-H), likely because cells 
have redundant mechanisms to resolve these structures and prevent bridge 




Figure 3.7 (Part I) – RAD54 promotes post-synaptic processing of recombination 
intermediates at ALT telomeres. 
A) Representative images of combined IF and DNA FISH for GFP (IF) and telomeres(FISH).  
HuO9 cells were transfected with GFP-BLM for 24 hrs followed by 20nM siRAD54#2 for 48 
hours. Scale bars = 10 µm 
B) Quantification of data shown in A.  Cells were counted positive if they contained at least 1 
colocalization event between GFP and telomeres.  Data were normalized to mock condition 
of each repeat.  At least 100 cells per condition per repeat were counted, n=4.  Values shown 
are mean±sd.  Conditions were analyzed using unpaired two-tailed student’s t-test.   
C) Representative western blot on samples from A-B. The lower band of the BLM doublet 
represents endogenous BLM, the upper band represents GFP tagged BLM.  
D) Representative images of IF-DNA FISH for MUS81 and telomeres. HuO9 cells were treated 
with 20nM siRAD54 #2 for 48 hours prior to staining. Scale bars = 10 µm 
E) Quantification of data shown in D. Cells were counted positive if they contained at least 1 
colocalization event between MUS81 and telomeres. At least 100 cells per condition were 
counted per repeat. n=5, values shown are mean±sd.  Conditions were analyzed using 
unpaired two-tailed student’s t-test.   
F) Representative images of UFB detection staining for PICH in HuO9 cells.  Cells were 
transfected with 20nM of noted siRNAs for 72 hrs. Scale bars = 10 µm 
G) Quantification of data shown in G.  Anaphases were scored from 4 independent experiments 
(mock), or 3 independent experiments (remaining conditions). Anaphases were considered 
positive for UFB if there was PICH staining between DAPI bodies. Single knockdown 
conditions had >50 anaphases scored.  Combined knockdown conditions had >88 
anaphases scored. Values shown are mean±sd.  Conditions were compared using one-way 

























































































































































































































































































































































































Figure 3.7 (Part II) – RAD54 promotes post-synaptic processing of recombination 
intermediates at ALT telomeres. 
H) Quantification of data shown in G.  Number of PICH stained UFBs counted per anaphase.  
Values shown are total counts over 3 independent experiments, shown mean±sem.  Total 
number of anaphases per condition were as follows: Mock n=134, siBLM/siSLX4 n=90, 
siRAD54/siSLX4 n=96, siRAD54/siBLM/siSLX4 n=88.  Conditions were compared using 
Kruskal-Wallis test followed by Dunn’s multiple comparison test.  
I) Representative images of UFB staining for TRF2 in HuO9 cells.  Cells were transfected with 
20nM siRAD54#2 alone or cotransfected siRAD54#2 and siSLX4 for 72 hours prior to 
staining. Scale bars = 10 µm 
J) Quantification of data shown in J. Anaphases were scored from 3 independent experiments. 
A total of 90 anaphases were scored per condition. Values shown are mean±sd.   Conditions 
were compared using one-way ANOVA followed by Dunnett’s multiple comparison test.   
K) Quantification of micronuclei from HuO9 cells treated with siRAD54#2 alone or siRAD54#2 
cotransfected with siSLX4 for 48 hours. Micronuclei containing telomeric DNA were identified 
using DAPI and telomere FISH.  Micronuclei were normalized to the number of nuclei 
counted.  Values shown are mean±sd. Conditions were compared using one-way ANOVA 

























































































































































































































































































































































































SLX4 had a significant increase in anaphase bridges coated by the telomere 
binding protein TRF2, (Fig 3.7I-J) demonstrating an accumulation of telomeric 
UFBs. Interestingly, while we observed a decrease in BLM recruitment to ALT 
telomeres in interphase, we did not observe a defect in BLM binding to UFBs in 
the absence of RAD54, suggesting that the defects we observe in anaphase 
were not simply a product of defects in BLM-mediated resolution of UFBs.  (Fig 
3.8C-D) In addition, we did not observe significant changes in the percentage of 
anaphases containing either PICH coated bridges or BLM coated bridges when 
RAD54 alone was depleted. (Fig 3.8E) Thus, the defects we observed in UFB 
resolution were not indirect effects due to loss of other known UFB resolving 
enzymes. 
The persistence of unresolved UFBs through telophase can lead to an 
accumulation of fragmented DNA and the formation of micronuclei.(120, 300, 
301) Moreover, depletion of the enzymes involved in UFB resolution, including 
PICH and BLM, leads to persistent UFBs and increase micronuclei 
formation.(300, 301) Likewise, when RAD54 was depleted in combination with 
SLX4, we observed a significant increase in the presence of micronuclei 
containing telomere FISH signal.  These results support the hypothesis that 
RAD54 functions to prevent the formation of UFBs at ALT telomeres and to 
maintain genome stability. (Fig 3.7K, Fig 3.8F) While we propose that the 
telomeric DNA found in the micronuclei is a result of fragmented telomeric UFBs, 





Figure 3.8 – RAD54 limits UFB formation and genome instability 
A) Representative western blot validating knockdown of BLM and RAD54 in HuO9.  Cells were 
treated with siRNAs for 72 hours prior to western blot.  
B) RT-qPCR data for SLX4 knockdown in HuO9 cells.  Cells were treated with siSLX4 or 
siRAD54#2 combined with siSLX4 for 48 hours.  Data shown are mean±sem for technical 
triplicates.  
C) Representative images of ultra-fine bridge (UFB) detection staining for PICH and BLM on 
HuO9 cells.  HuO9 cells were transfected with siRAD54#2 for 72 hrs. Scale bars = 10 µm 
D) Quantification of data shown in C.  At least 60 total PICH bridges were counted in each 
condition over 3 biological replicates. A PICH bridge was considered positive for BLM if there 
was evidence of BLM staining over all or part of the PICH coated bridge. Values shown are 
mean±sd.  Values were compared using two-tailed unpaired student’s t-test. 
E) Quantification of data shown in C.  At least 90 total anaphases were scored over 3 biological 
replicates.  An anaphase was considered positive if it contained 1 or more PICH or BLM 
bridges.  Values shown are mean±sem.  Conditions were compared using a two-way ANOVA 
followed by Tukey’s multiple comparison test.  
F) Representative DNA FISH images of HuO9 cells treated with siRAD54#2 and siSLX4 for 48 
hours with and without a micronucleus containing telomere FISH signal (indicated by white 
























































































































Given that C-circles decrease in the absence of RAD54, we do not expect that 
ECTRs fully explain the increase in telomeric DNA containing micronuclei 
observed upon RAD54 and SLX4 depletion.   
Concluding remarks 
Loss of RAD54 blunts elongation events at ALT telomeres in a manner 
dependent on the ATPase activity and oligomerization of RAD54. (Fig 3.5A-B, G-
H)   This observation suggests that RAD54 is promoting branch migration of 
recombination intermediate structures formed at ALT telomeres. Recombination 
intermediate structures can be resolved through dissolution or nucleolytic 
cleavage, or if left unresolved will lead to HR-UFBs.(120) The combined 
depletion of RAD54 and SLX4 led to a significant increase in UFBs at ALT 
telomeres. (Fig 3.7F-J) The BLM protein has both helicase and branch migration 
activities and has been demonstrated to regulate ALT activity. In addition to its 
role in the BTR dissolvasome, BLM contributes to BIR at ALT telomeres by 
cooperating with DNA2 to promote long-range 5’ to 3’ resection of broken DNA 
ends during pre-synapsis, generating structures capable of initiating strand 
invasion and inducing telomere elongation events.(73, 251) Several recent 
studies have suggested that the branch migration activity of BLM may be 
secondary at ALT telomeres as compared to other functions of BLM, such as its 
ability to recruit TOP3A-RMI1-RMI1 or promote long-range resection.(73, 251) 






Figure 3.9 – Proposed model of RAD54 activity at ALT telomeres 
RAD54 functions downstream of presynaptic events to regulate the processing of D-loop 
structures, promoting telomere synthesis via BIR at ALT telomeres.  RAD54 branch migration 
activity may function coordinately with BLM to promote BTR-dependent dissolution of 
recombination intermediates.  Specifically, RAD54 may promote branch migration and ultimately, 
dissolution through regions of heterology either in the D-loop or that arise during error-prone DNA 
extension events. Alternatively, RAD54 may function to dissolve heterologous recombination 
intermediates to promote formation of more homologous intermediates that will lead to higher 
fidelity telomere extension events. In the absence of RAD54, like in the absence of BLM, ALT 






telomeres may then depend on other cellular enzymes, such as RAD54. (Fig 3.9) 
This possibility is of particular interest because RAD54 has been shown to have 
higher branch migration efficiency than BLM on partial X junctions,(289, 290) the 
DNA joints formed during BIR.(292)  
BIR is known to be an error-prone process and likely to introduce 
mismatches into telomeric DNA during POLD3 synthesis.(132, 133) MUS81 has 
been implicated in limiting the mutagenic nature of BIR, especially at repetitive 
DNA elements, by cleaving D-loop structures and limiting the duration and length 
of extension events.(133) We observed that when RAD54 is depleted, there was 
an increase in MUS81 recruitment to ALT telomeres (Fig 3.7D-E) and a 
concomitant decrease in telomere synthesis events, (Fig 3.5A-B) suggesting that 
RAD54 may be promoting these long-range BIR synthesis events that are 
otherwise terminated through MUS81 cleavage of the D-loop. Given the known 
interaction between RAD54 and MUS81(295), RAD54 may function to regulate 
the substrate specificity of the MUS81 endonuclease at ALT telomeres.(302) 
In addition to favoring partial-X junctions, RAD54 promotes branch 
migration through sites of heterology more efficiently than BLM by an order of 
magnitude.(292) DNA heterology can form during strand invasion when the 
invading strand lacks complete homology with the template DNA. While no 
studies have looked specifically at the formation of DNA heterology at ALT 
telomeres, DNA mismatch repair proteins MSH2/6 are shown to associate with 




increase in variant telomeric repeats at ALT telomeres,(141) which may lead to 
DNA heterology during search and capture steps of recombination. Telomeric D-
loop structures containing sites of heterology may be tolerated and extended, 
dependent on the branch migration activity of RAD54.  Alternatively, these 
structures may be dissolved by RAD54 prior to DNA synthesis in order to limit 
heterologous recombination and provide an additional opportunity for the strand 
invasion machinery to form a productive D-loop. (Fig 3.9) Both possible functions 
of RAD54 would support de novo telomere synthesis and elongation events. 
Together our data highlight a previously uncharacterized role for the translocase 






CHAPTER FOUR: FINAL THOUGHTS AND FUTURE DIRECTIONS  
Telomere elongation by ALT resembles a type of DNA repair called break-
induced replication, which is known to repair single ended DNA DSBs caused by 
unresolved replication stress. Although the cellular changes leading to initiation 
of ALT activity is still under investigation, ALT cells contain several unique 
characteristics. ALT cells frequently harbor mutations in the ATRX/DAXX genes, 
which code for a chromatin-remodeling complex, leading to the hypothesis that 
altered chromatin may prime cells for telomere recombination. ALT cells also 
show evidence of cellular phenotypes consistent with a chronic recombinogenic 
state. These phenotypes include 1) the formation of APBs, which are nuclear 
depots containing telomeres, PML and DNA repair proteins, 2) increased ECTR, 
which are thought to be DNA byproducts of recombination trimmed off during or 
after recombination, and 3) elevated levels of T-SCE, which are indicative of 
active HR at ALT telomeres but not elongation events. Although advances have 
been made in defining the ALT mechanism, there are still many remaining 
questions, including whether ALT can be targeted therapeutically.  
 
Section 1: Targeting telomere maintenance mechanisms 
therapeutically  
Telomere maintenance mechanisms have long been sought after as a 
targeted therapeutic approached for cancer because telomere length is not 




maintenance is required in most cancers. Despite the fact that telomerase 
inhibitors have been developed, there has been little clinical success. (200, 303) 
The difficulties in developing a therapeutic approach targeting telomerase likely 
lies in the fact that there would need to be a delay between onset of therapy and 
measurable clinical response, to allow for sufficient telomere attrition to induce 
cellular crisis. Depending on the starting telomere length and the population 
doubling time of the cancer cells, this delay could be significant enough to allow 
for terminal disease progression. This delay limits the use of telomerase 
inhibitors for first line therapy, though they may still be beneficial for maintenance 
therapy to prevent recurrence. Telomerase inhibitors for maintenance therapy 
could be particularly useful if short telomere length is utilized as a positive 
predictive biomarker in patient selection, as patients with short telomeres would 
be expected have a reduced delay between therapy onset and clinical 
response.(303, 304) There is evidence that when telomerase is extinguished, 
there is selective pressure to activate the ALT pathway, indicating that ALT may 
develop as a resistance mechanism to telomerase inhibitors.(305) Additionally, 
there is a small subset of cancer cells that lack telomere maintenance 
mechanisms, called ever-shorter-telomere (EST) cells.(306) These cells seem to 
have undergone an extensive elongation mechanism at some point, and have 
long enough telomeres to divide sufficiently to cause disease without ever 
establishing replicative immortality. EST cells would not respond to telomerase or 




Currently, there are no therapies targeting the ALT pathway, though a 
number of drugs targeting DNA repair pathways have been developed in recent 
years.(307–309) Targeting DNA damage repair pathways has had clinical 
success in a number of indications. First, BRCA1/2 deficient cancers, which are 
deficient in HR repair, have been shown to be incredibly sensitive to inhibition of 
poly-ADP-ribose polymerase (PARP).(310–314) Germline mutations in BRCA1 
or 2 negatively affects cellular response to replication stress and DNA DSBs, 
causing an elevated basal level of genome instability and making these patients 
highly susceptible to cancer. The PARP family of proteins, especially PARP-1, 
function as crucial sensors and regulators of DNA damage response, promoting 
recruitment of machinery for nucleotide excision repair, base excision repair, 
NHEJ and HR.(315, 316)  It is hypothesized that PARP inhibition traps PARP on 
damaged DNA or stalled replication forks, leading to the formation of a DSB, 
which cannot be efficiently repaired due to the underlying defects in HR in 
BRCA1/2 deficient cells. Thus, genome instability is exacerbated to a fatal 
degree, creating synthetic lethality. Second, there are clinical trials combining 
traditional genotoxic chemotherapy with inhibitors of DNA damage response. In 
these trials, drugs such as ATR inhibitors are used to enhance the genotoxicity of 
chemotherapy, however combinations of DNA damage response inhibitors and 
chemotherapy have also caused significant dose limiting toxicities.(307, 317) The 
profound clinical effect of PARP inhibition in specific patient populations 




with altered DNA repair mechanisms, or cells that maintain high basal levels of 
genome instability, such as ALT cells 
Due to the high levels of replication stress and reliance on HR, ALT cells 
have been shown to be hypersensitive to ATR inhibition in vitro.(63) While ATR 
inhibitors have shown some success in clinical trials, especially in combination 
with traditional chemotherapy, they have not been tried as monotherapy or 
against ALT positive tumors specifically. The development of successful targeted 
therapies for ALT positive tumors depends on two important factors. First, we 
need to be able to reliably and precisely identify patients with ALT positive 
tumors. Second, we need to identify druggable targets within the ALT pathway 
that induce apoptosis specifically in ALT cells, while sparing normal somatic 
cells. Learning from the limited success of telomerase inhibitors, inhibiting targets 
within the ALT pathway would ideally induce apoptosis without relying on 
replication dependent telomere attrition.  
 
Section 2: The genetics of ALT positive tumors 
There are several phenotypes associated with ALT that may aid in 
identifying patients with ALT positive tumors. First, C-circles have been shown to 
closely correlate with ALT activity and are detectable in tumor samples.(213) 
There are ongoing efforts to improve the specificity and throughput of the C-circle 
assay to determine whether it is a suitable clinical diagnostic test.(297, 318)  




FISH,(199, 203) these foci may represent very long telomeres or telomeric DNA 
that has clustered to promote HR. While this technique can be multiplexed into 
tissue microarrays, giving it sufficient throughput, this phenotype is confounded 
by the recent discovery of a small subset of tumors that lack telomere length 
maintenance mechanisms, termed the ever-shorter telomeres (EST) 
phenotype.(306) EST cells have highly extended telomeres that allow for a large 
enough number of cell divisions to cause disease, creating clinical manifestations 
of cancer before telomere attrition induces senescence or crisis.  EST cells are 
likely to have undergone an extensive telomere elongation event at some point, 
leading to very long telomeres. Because EST telomeres are so long, they may 
appear as ultra-bright telomeric foci by DNA FISH, similar to ALT telomeres. 
However, EST cells do not utilize ALT, and therefore would not respond to 
inhibitors targeting ALT.   
Genetics can help to identify ALT positive tumors, starting with ATRX and 
DAXX mutations, which strongly correlate with the presence of ALT activity.(203, 
215)  In one study on pancreatic neuroendocrine tumors, 100% of tumors with 
ATRX or DAXX mutations were ALT positive, however 6 of 20 tumors without 
mutations were also ALT positive, indicating that ATRX and DAXX mutations 
alone are insufficient to identify all ALT tumors within a population.(203) While 
confirmation of ALT status currently requires phenotypic assays, such as the C-




underlying ALT activation may enable future methods of predicting ALT status by 
looking at mutations or deletions in a subset of genes.  
While genetic mutations in ATRX and DAXX correlate with ALT status, it 
was recently found that several other proteins known to regulate ALT activity also 
show evidence of genetic mutations or deletions in ALT positive tumors, such as 
SMARCAL1 and SLX4IP as discussed in this body of work.(227) Emerging data 
on the genetics of ALT tumors suggest that instead of relying solely on 
dysfunction of the ATRX/DAXX chromatin-remodeling complex, activation of ALT 
resembles a multi-genic disorder, with multiple somatic mutations or genetic 
alterations contributing initiation of the ALT phenotype. Additionally, these data 
lead us to hypothesize that ALT may in fact encompass a family of pathways that 
varies slightly from tumor to tumor in both its initiation and regulation. For 
instance, ALT positive tumors with ATRX deficiency may behave slightly 
differently than SLX4IP or SMARCAL1 deficient tumors. In support of this 
hypothesis, our lab has previously shown that SMARCAL1 is required for the 
regulation of replication stress at ALT telomeres, and depletion of SMARCAL1 
leads to a telomere dysfunction caused by a hyper-recombinogenic 
phenotype.(212) However, recently several cell lines and tumors were identified 
that carry mutations or total loss of SMARCAL1 while maintaining functional ALT 
pathways,(227, 260) indicating that these ALT positive samples have an 
alternate way of keeping replication stress at manageable cellular levels in the 




have features in common, such as chronic replication stress, telomere-clustering 
events in APBs, and POLD3-mediated telomere elongation, we expect that there 
may be inter-tumor heterogeneity in the initiation and maintenance of ALT.  
Through this work we also demonstrated that understanding the genetics 
of ALT depends upon thorough investigation into genes of interest. Given the 
highly rearranged nature of many cancer genomes, simply looking at the 
sequences of coding exons may be insufficient for capturing alterations in the 
genes associated with ALT. For example, prior to this work, the ALT positive 
osteosarcoma cell line G292 was reported to be wild-type for DAXX through 
whole exome sequencing and immunohistochemical approaches.(215) While 
G292 cells harbor a t(6;16) translocation event, all of the coding exons for DAXX 
are present in the genome and a protein product is translated, even though that 
protein does not function like wild-type DAXX. This work provides rationale for 
more in depth analysis of the genes known to be associated with ALT. These 
types of structural rearrangements would also need to be taken into account if 
genetic aberrations were used for identifying ALT positive tumors clinically.  
There is still significant work to be done to fully understand the genetics 
underlying ALT activation. In the majority of the samples in our panel of 
osteosarcoma cell lines and tumors, we have identified genetic defects in 
regulators of ALT, including ATRX, DAXX, SMARCAL1 or SLX4IP. While loss of 
any of these genes is sufficient to induce ALT activity, interestingly, alterations in 




of these genes alone primes the cell for ALT. It would be interesting to 
investigate whether the mutual exclusivity of ALT-associated genetic mutations 
observed in these studies holds true across a larger dataset of ALT positive 
tumors. Moreover, even within our dataset, there are ALT positive tumors lacking 
mutations in any of these four genes, and we expect there to be additional 
genetic aberrations identified that contribute to ALT activation. Further study into 
the ALT mechanism may help identify additional genetic events that prime cells 
for ALT activation. Furthermore, fully characterizing the genetic aberrations 
associated with ALT may provide a more straightforward method to identify ALT 
tumors than the current battery of phenotypic analyses. However previous 
characterization of ATRX/DAXX,(203, 215, 227) combined with the work 
presented here demonstrate inconsistency in the types of aberrations found in 
these genes, including full gene deletions, coding mutations, and structural 
rearrangements. The wide variety of somatic genetic alterations, combined with 
the highly rearranged nature of the genomes in tumor types such as 
osteosarcoma, may still prove to be a barrier to using genetics alone to reliably 
identify ALT positive tumors. 
 
Section 3: Understanding the ALT mechanism 
 Great strides have been made in characterizing the mechanism of ALT 
telomere elongation and defining the roles played by many DNA repair proteins. 




relying largely on RAD51-independent strand invasion, and then utilizing both 
Polη and Polδ for DNA synthesis events after the formation of a D-loop.(122, 
123, 152, 169, 214, 248, 251) Recent work identified critical roles for BLM and 
SLX4 in processing recombination intermediates at ALT telomeres through 
dissolution or cleavage, respectively.(73, 260) Previous work also established 
that telomere sister chromatid exchange events, previously used as a marker of 
ALT activity, do not in fact represent elongation events. They are instead thought 
to be a result of D-loop cleavage, not branch migration. SLX4IP is a critical 
regulator of BLM and SLX4 at ALT telomeres, and therefore plays an important 
role in coordinating productive recombination at ALT telomeres.(260) Despite 
these advances in understanding the formation, elongation, and resolution of 
telomeric recombination intermediates, there are still no targeted therapies 
available for patients harboring ALT-positive tumors.  
Given that replication stress causes the uncoupling of the replicative 
helicases and polymerases, one outcome of chronic replication stress at ALT 
telomeres is the persistence of RPA-coated single stranded DNA, and 
subsequent activation of ATR.(39, 57, 63, 93) Our lab has previously 
demonstrated that ATR depletion or inhibition in ALT positive cancer cell lines 
disrupts ALT activity, ultimately leading to chromosomal fragmentation and 
apoptosis.(63) Across a panel of cell lines, ALT positive cell lines are around 20-
fold more sensitive to ATR inhibitors than telomerase positive cell lines. We 




immunocompromised mice. There is currently a dearth of models to study 
tumorigenesis of ALT positive osteosarcoma in vivo. While there are genetic 
mouse models of osteosarcoma,(319–321) the regulation of replicative 
immortality and telomere maintenance in mice differs significantly from humans. 
Telomerase is widely expressed in mice, and mice harbor much longer telomeres 
than human cells, ranging in size from 40-80 kilobases as compared to 10-15 
kilobases in humans.(322, 323) While ALT can be induced in murine cells by 
taking cells lacking telomerase through crisis in vitro,(324) to date, there are no 
genetic models of cancer in mice that activate ALT. Instead, we rely on 
engrafting human tumors into mice, either using cell line xenografts or patient-
derived xenografts.  
Xenograft tumors do not allow for the study of ALT development, but are 
useful models for studying potential ALT-targeted therapies. Using the 
osteosarcoma cell line, HuO9, I established ALT positive xenograft tumors in 
SCID mice. We established a treatment protocol for the ATR inhibitor, VE-822, 
based on previous studies.(317) We found that VE-822 failed to induce any 
growth defect or tumor regression in vivo. (Fig 4.1A) HuO9 cells are highly 
sensitive to ATR inhibition in vitro,(63) therefore we hypothesized that VE-822 
was failing to inhibit ATR kinase activity in the tumor. To determine whether VE-
822 was inhibiting ATR, I looked at the phosphorylation of a downstream target 
of ATR, CHK1. I induced DNA damage by treating the animals with a single dose 




response to DNA damage, phosphorylating CHK1 at serine-345. When the mice 
were treated with VE-822, ATR kinase activity was inhibited for at least one hour. 
However, by 4 hours post-treatment with VE-822, there was evidence of 
phospho-CHK1, (Fig 4.1B) indicating that ATR was only inhibited for a short 
amount of time in vivo. Furthermore, the treatment regimen included 3 days in 
which animal were not treated at all. Together, this led to a limited duration of 
ATR inhibition that was insufficient to cause tumor regression.  
Given that the limitations of this study seemed to be drug specific, we do 
not believe these data invalidate ATR as a potential therapeutic target for ALT 
positive cancers. VE-822 has previously been used in combination with 
genotoxic chemotherapy,(317) which may require different pharmacokinetics to 
achieve clinical efficacy compared to using ATR inhibitors as a monotherapy. In 
future studies, we aim to use next generation ATR inhibitors, and potentially 
collaborate to develop an ATR inhibitor designed for extended target inhibition.  
Additionally, in future studies, we plan to utilize the laboratory’s 
established panel of ALT positive osteosarcoma PDX models to test anti-tumor 
efficacy. PDX models have been demonstrated to better capture tumor 
heterogeneity and be more predictive of drug response than xenograft models 
derived from cancer cell lines.(325–327) Additionally, given that our genetic 
studies suggest that ALT may vary in tumors with different genetic backgrounds, 
we hope to capture both intra- and inter-tumor heterogeneity using our panel of 





Figure 4.1 – Treatment of ALT positive xenograft with ATR inhibitor 
A) 5 x 106 HuO9 cells were engrafted subcutaneously into SCID mice (Taconic) and allowed to 
grow until they reached 150-200 mm3. Mice were randomized and treated with 60 mg/kg VE-
822 (n=6) or vehicle (n=4, 10% vitamin E TPGS) by oral gavage for 4 days, followed by a 3 
day break. Data were compared using two-way ANOVA followed by a Bonferroni multiple 
comparison test. * p =0.04 
B) Tumors were engrafted as in A. When the tumors reached 150-200 mm3, animals were 
treated with a single dose of 100 mg/kg gemcitabine immediately followed by 60 mg/kg VE-
822 or vehicle. Animals were sacrificed after given time, tumors were excised immediately 
and flash frozen.  Tumor tissue was lysed in RIPA buffer and homogenized with a dounce 
homogenizer prior to running on western blot.  
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microenvironment or the immune system, given that the tumors are implanted 
into immunocompromised mice. It was recently suggested that the ECTRs 
present in ALT cells escape to the cytosol, activating Type I interferon response 
through the nucleic acid sensing pathway, cGAS-STING,(328) indicating that 
ALT activity may create a unique immunological signature in human cancer. PDX 
tumors can be implanted into mice with humanized immune systems. This 
system could provide a more representative and complete model of ALT positive 
osteosarcoma, and allow for the testing of ALT inhibitors combined with potential 
immunotherapy modalities. (329–331) 
While ATR may still be a viable therapeutic target for ALT, we were 
interested in further elucidating the mechanism of ALT, potentially identifying 
alternate therapeutic targets. Through this body of work we characterized the role 
of RAD54 in ALT telomere elongation. RAD54 is a known regulator of HR and 
has not previously been investigated in ALT positive cancers. Additionally, unlike 
many DNA repair proteins, RAD54 is not embryonic lethal(332) and therefore we 
wanted to understand the role RAD54 was playing in ALT to determine if ALT 
positive cells may uniquely rely on RAD54.  
RAD54 has primarily been studied in vitro and in yeast, and has functions 
at many stages during HR, ranging from pre-synapsis to post-synaptic 
processing of branched DNA structures.(96, 98, 107, 109, 287, 288, 290–292, 
298, 99–106) Our work demonstrated that RAD54 plays an important role in 




Through its branch migration activity, RAD54 promotes non-S-phase DNA 
synthesis events at ALT telomeres, which are thought to represent telomere 
elongation events. Like the BTR complex, RAD54 promotes dissolution of D-
loops formed at ALT telomeres, thereby promoting telomere elongation and 
preventing the persistence of toxic unresolved recombination intermediates. BLM 
has long been known to be required for ALT telomere maintenance. Given its 
role as a helicase in the BTR dissolvasome complex, it was hypothesized to 
promote branch migration of D-loops.(70, 73, 333) However, recent studies 
suggest that, in fact, the role of BLM in the BTR complex at ALT telomeres may 
be secondary to its role in promoting long-range resection of broken DNA 
strands.(73, 251) If BLM is functioning primarily outside of the BTR complex, it 
would suggest that ALT cells require a different enzyme to promote branch 
migration and subsequent dissolution of D-loops formed at ALT telomeres.  
Processing of D-loops is necessary to prevent persistent DNA 
entanglements as the cells proceed into mitosis, which can lead to the formation 
of ultrafine anaphase bridges (UFBs).(116, 120) Our data demonstrate that BLM 
and RAD54 act epistatically to prevent the formation of UFBs in ALT cells, likely 
by promoting dissolution of D-loops. However, the interplay and/or coordination 
between RAD54 and BLM activity at ALT telomeres is still unknown. RAD54 and 
BLM have been reported to interact, with the N-terminal domain of BLM 
stimulating RAD54 ATPase activity,(334) however we were unable to detect this 




the ability to branch migrate, they differ in their enzymatic functions, RAD54 
being a DNA translocase and BLM being a helicase. It is possible that combined 
helicase and translocase activities of BLM and RAD54 and BLM coordinate 
branch migration of D-loops at ALT telomeres. Due to its lack of helicase activity, 
RAD54 is unable to unwind secondary structures and therefore could rely on 
BLM to dissolve secondary structures ahead of the DNA synthesis machinery.  
RAD54 and BLM also differ in their polarity, branch migration efficiency, 
and ability to bypass regions of heterology.(292) Based on these differences, an 
alternative hypothesis to the relationship between RAD54 and BLM is that each 
protein may work at a specific subset of D-loops, depending on the D-loop 
composition and structure. For instance, RAD54 is known to promote branch 
migration over regions of heterology incredibly efficiently, and therefore RAD54 
may function primarily at D-loops that contain mismatches. Given that BLM is not 
able move over structures containing heterology, in the absence of RAD54 these 
D-loops would otherwise be cleaved or left unresolved. Therefore, the branch 
migration activity of RAD54 may allow for productive extension events to occur at 
a higher percentage of D-loops formed. Further studies into the role of RAD54 at 
ALT telomeres are needed to determine whether RAD54 is coordinating with the 
BTR complex to promote dissolution of D-loops, or whether each branch 
migration enzyme is working on a unique subset of substrates.  
We hypothesize that there is enrichment in DNA heterology at ALT 




telomeres are known to have a high prevalence of non-canonical repeats, such 
as TCAGGG (C-type repeat) or TGAGGG (G-type repeat),(141) which could 
potentially come from errors incorporated during BIR, or from the incorporation of 
subtelomeric sequence during recombination. Given the high prevalence of non-
canonical repeats, it is reasonable to assume that during homology search and 
strand invasion a perfectly homologous template is not always identified. D-loops 
at ALT telomeres may contain regions of heterology consisting of a mixture of 
canonical and non-canonical repeats at the site of synapsis. In support of this 
hypothesis, several data sets have identified components of the mismatch repair 
machinery to be enriched at ALT telomeres, including the sensors of DNA 
mismatches, MSH2 and MSH6.(168, 169) Future work will include determining 
whether RAD54 is specifically recruited to sites of heterology at ALT telomeres.  
The migration of the D-loop down a template strand coincides with the 
extension of the invading telomeric DNA by Polη and Polδ. Additionally, the 
resolution of the D-loop, either by dissolution or cleavage is necessary to avoid 
formation of UFBs. Together, this suggests that post-synaptic processing of the 
D-loop formed at ALT telomeres is a critical step of the ALT pathway, both for 
promoting telomere elongation and for maintaining genome stability, and 
therefore could be a potential point of therapeutic intervention. Alexander Mazin’s 
group, which has done extensive work characterizing the in vitro activities of 
RAD54, recently identified a small molecule that specifically inhibits the branch 




ability of RAD54 to dissolve branched DNA structures in vitro without interfering 
with other activities, such as stabilizing RAD51-nucleofilaments and promoting 
strand invasion. The small molecule identified, called streptonigrin, is a 
chemotherapy drug that was abandoned during clinical development due to 
toxicities.(296, 335–337) However, we propose that streptonigrin acts as a proof 
of principle that the branch migration activity of RAD54 can specifically be 
targeted pharmacologically. In future studies, the chemical structure of 
streptonigrin could be used as a starting point to develop more specific inhibitors 
of RAD54-mediated branch migration.   
Based on our studies, short-term depletion of RAD54 does not lead to cell 
death or genomic instability. However, additional studies need to be done in 
order to determine if long-term depletion of RAD54 has an effect on telomere 
length maintenance in ALT cells. We would hypothesize that in the absence of 
RAD54, recombination intermediates at ALT telomeres would be more likely to 
be resolved through cleavage and telomere sister chromatid exchanges (T-SCE).  
Given that T-SCE do not represent telomere elongation, long-term depletion of 
RAD54 may result in telomere attrition over time. However, it is also possible that 
in the absence of RAD54 cells would engage compensatory mechanisms to help 
dissolve D-loop structures, this could include other RECQ1 family helicases.   
Through this work, we have demonstrated that RAD54 functions at ALT 
telomeres to promote ALT activity and telomere synthesis. Its role in resolving 




preventing the formation of UFBs. If left unresolved, UFBs can break, leading to 
micronuclei formation, and chromosomal translocations and fusion events. 
Interestingly, UFBs have also been shown to be regulated by TOPBP1,(338, 
339) one of two known ATR activating proteins. The association of TOPBP1 with 
UFBs suggests that ATR may also play an important role in preventing or 
resolving UFBs. Given that both RAD54 and ATR function to prevent UFB 
formation, it would be interesting to test whether combined inhibition of RAD54 
and ATR may have synergistic effects in ALT cells or tumors, inducing elevated 
levels of genome instability and subsequent apoptosis.  
 
Section 4: Conclusions 
 The ALT pathway is a BIR-like pathway leading to replicative immortality 
in around 10% of cancers. We demonstrated a critical role for RAD54 in 
promoting ALT telomere elongation. Additionally, through this work, we expanded 
an understanding of genetic events underlying ALT activity. Together these data 
suggest that, while ALT positive cancers utilize a common BIR-like mechanism, 
ALT tumors may establish the recombinogenic state of the telomeres through 
various mechanisms. Ultimately, this body of work contributes to ongoing efforts 
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